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 SUMMARY 
 
Chronic myeloid leukemia (CML) is a clonal disorder of the hematopoietic stem 
cell caused by the BCR-ABL receptor tyrosine kinase. Imatinib mesylate (IM) is 
an inhibitor of BCR-ABL and has been approved for the treatment of CML. IM is 
well tolerated and highly efficacious as it induces stable long-term remissions in 
the vast majority of patients. Despite its efficacy, a still unresolved issue 
associated with IM therapy is IM resistance in progressed phases of CML and 
long-term disease persistence. It has been shown that BCR-ABL mRNA and 
BCR-ABL-positive progenitor and stem cells remain detectable after years of 
therapy. Based on the BCR-ABL expression analysis and short term IM exposure 
experiments of IM-naïve, first diagnosis CML precursor cells it has been 
suggested that BCR-ABL over-expression contributes to a major extend to the 
incapability of IM to kill and eradicate primitive precursors and CML stem cells. 
Interestingly, the BCR-ABL expression level in actual persisting CML precursor 
clones, and the impact of long term IM therapy on the eradication of CML 
precursors from different bone marrow compartments was never been thoroughly 
investigated. 
Here we studied a putative novel IM persistence mechanism by directly 
investigating in residual BCR-ABL-positive progenitor and stem cell clones in 
chronic phase CML patients in major molecular remission (MMR) under IM. We 
could first show that IM not only eliminates BCR-ABL positive cells from both 
primitive (stem cell containing) and more mature bone marrow precursor 
compartments but also that,  in contrast to the currently proposed model, 
persisting primitive and mature BCR-ABL positive colony forming clones (CFU) 
expressed significantly less BCR-ABL than CML CFU isolated from initial 
diagnosis  patients. Indeed, lower BCR-ABL expression reduces IM sensitivity of 
primary bone marrow progenitors engineered to express BCR-ABL. Whereas high 
BCR-ABL expression level increased IM responsiveness but also the frequency of 
BCR-ABL kinase mutation development as the most important IM resistance 
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 mechanism. This would explain the low propensity of secondary IM resistance in 
patients, which do achieve a good molecular remission with IM. 
 Another regulator of BCR-ABL kinase point mutation development has been 
identified with ICSBP, an interferon regulated gene that was previously found by 
our group to be downregulated in CML. Lack of ICSBP expression in murine 
myeloid 32D-BA cells conferred BCR-ABL independent IM resistance and limits 
the development kinase point mutations. Together, here we described two novel 
and clinically relevant mechanisms of CML persistence and resistance under IM, 
which may provide a novel perspective for reassessing treatment strategies aiming 
at eradicating residual disease in CML and to overcome IM resistance.  
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 ZUSAMMENFASSUNG 
 
Die chronische myeloische Leukämie basiert auf einer klonalen Transformation 
hämatopoetischer Stammzellen, für die die Translokation t(9;22)(q34;q11) mit 
Entstehung der konstitutiv aktivierten BCR-ABL Tyrosinkinase kausal 
verantwortlich ist.  
IM ist ein spezifischer Inhibitor von BCR-ABL, der speziell für die Behandlung 
der CML entwickelt wurde und klinisch hochwirksam ist. Die große Mehrheit der 
mit IM behandelten Patienten erreichen stabile Langzeitremissionen. Trotz dieser 
enormen Wirksamkeit gibt es weiterhin zwei entscheidende Probleme unter IM. 
Zum einen kommt es bei einem Teil der Patienten unter IM zur 
Resistenzausbildung. Andererseits scheint die Substanz zwar antiproliferativ zu 
wirken, aber nicht in der Lage zu sein, CML Progenitor- und Stammzellen 
abzutöten. Dies führt zu Persistenz der Erkrankung im Knochenmark von CML 
Patienten und macht eine IM Dauertherapie als Standard erforderlich. Basierend 
auf in vitro Untersuchungen wurde eine Überexpression von BCR-ABL in CML 
Stammzellen unbehandelter CML Patienten als ein wesentlicher Mechanismus für 
IMpersistenz proklamiert, obwohl die BCR-ABL Expressionshöhen 
persistierender CML Vorläuferzellen unter IM unbekannt sind. Ebenso unklar ist, 
ob IM in vivo in der Tat nicht in der Lage ist, CML Stammzellen abzutöten.  
Im Rahmen dieser Doktorarbeit wurde ein neuartiger IMpersistenzmechanismus 
beschrieben. Im Knochenmark von molekular in sehr guter Remission 
befindlichen Patienten unter IM wurde nach persistierenden CML Klonen gesucht, 
deren Frequenz und BCR-ABL Expressionshöhen bestimmt und mit denen von 
CML Patienten bei Erstdiagnose verglichen. Im Gegensatz zum aktuell etablierten 
Persistenzmodell konnte gezeigt werden, dass IM zu einer deutlichen Abnahme 
der BCR-ABL positiven Stammzellen bei Patienten in Remission unter IM führt 
und dass persistierende Klone BCR-ABL nicht überexprimierten, sondern nur sehr 
geringe BCR-ABL Mengen aufwiesen. Es konnte dann an primären 
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 Knochenmarkzellen gezeigt werden, dass eine niedrige Expression von BCR-ABL 
in der Tat zu einer IMresistenz führt, währenddessen die BCR-ABL 
Überexpression eine höhere Empfindlichkeit auf IM induzierte, andererseits aber 
auch die Entstehung von BCR-ABL Kinasemutationen als einem wesentlichen 
Mechanismus von IM resistenz katalysierte. Dies würde erklären, warum 
Patienten mit guter molekularer Remission unter IM eine vernachlässigbare Rate 
an sekundär IMresistenzausbildung aufweisen. 
Etwa 80% der CML Patienten zeigen eine reduzierte Expression des 
interferonregulierten Faktors, ICSBP. Die fehlende Expression von ICSBP wurde 
hier als ein BCR-ABL unabhängiger Mediator von IMresistenz und 
Kinasemutationsentstehung identifiziert.  
Diese Arbeit beschreibt somit zwei neue und potentiell klinisch relevante 
Ursachen von IM resistenz und –persistenz. Deren Kenntnis könnte zur Re-
evaluation von Strategien zur Eradikation residueller CML Stammzellen und dem 
Überkommen von IM resistenz beitragen. 
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 1. ABBREVIATIONS 
All units of measurement are abbreviated according to the International System of 
units (SI). 
A adenosine 
ABL abelson 
AID activation-induced cytidine deaminase 
ALL acute lymphoblastic leukemia 
APS ammoniumperoxodisulfat 
ATP adenosine triphosphate 
BC blast crisis 
BCR breakpoint cluster region 
bp base pair 
BSA bovine serum albumin 
C cytosine 
cDNA complementary DNA 
CML chronic myeloid leukemia 
CMP common myeloid progenitor 
DA dasatinib 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
dNTPs 2'-deoxynucleoside-5'-triphosphates 
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 DTT dithiothreitol 
EDTA ethylene diaminetetraacetic acid 
EtBr ethidium bromide 
FACS fluorescence-activated cell sorter 
FCS fetal calf serum 
G-CSF granulocyte colony-stimulating factor 
GM-CSF granulocyte/macrophage colony-stimulating factor 
GMP granulocyte macrophage progenitor 
HEPES (2-Hydroxyethyl)-1-piperazineethanesulphonic acid 
HRP horse radish peroxidase 
HSC hematopoietic stem cells 
IAD IRF-association domain 
ICSBP interferon consensus sequence binding protein 
IFN interferon 
IRF interferon regulatory factor 
ISRE IFN stimulated response elem 
IL-3 interleukin-3 
IL-6 interleukin-6 
IM Imatinib mesylate (IM, Gleevec® ) 
IMDM Iscoves Modified Dulbecco’s Medium 
vi 
 
 kb kilobase pair 
kD kilodalton 
Lin- lineage negative 
MRD minimal residual disease 
MEP megakaryocyte erythroid progenitor 
NaCl sodium chloride 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
Ph+ philadelphia chromosome positive 
PI3K phosphatidylinositol 3-kinase 
PMSF phenylmethylsulfonyl fluoride 
RNA ribonucleic acid 
rpm retation per minute 
RT-PCR  reverse transcription PCR 
SDS sodium-dodecyl-sulphate 
TAE tris-acetate-EDTA buffer 
TBE tris-borate-EDTA buffer 
TE tris-EDTA 
TKI tyrosine kinase inhibitor 
vii 
 
 Tris tris(hydroxymethyl)-amino-methane 
U unit 
wt wild type 
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Introduction 
2 INTRODUCTION 
2.1 Chronic Myeloid Leukemia (CML) 
 
Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder (Baikie et 
al., 1960). In 1960 Nowell and Hungerford described a shortened chromosome 22 
known as Philadelphia chromosome (Ph chromosome) generated from 
chromosomal translocation. This translocation juxtaposes the c-abl gene on 
chromosome 9 and the bcr gene on chromosome 22 as t (9;22)(q34;q11) generates 
the BCR-ABL fusion gene  (Figure1) (Nowell and Hungerford, 1960; Rowley, 
1973). CML was the first human disease to be associated with a consistent 
cytogenetic abnormality, BCR-ABL, as well as the first cancer to be treated with 
molecular targeted therapy. (Daley et al., 1990; Fialkow et al., 1977; Heisterkamp 
et al., 1990; Heisterkamp et al., 1985; Konopka et al., 1985; Nowell and 
Hungerford, 1960) 
 
Figure 1: The Philadelphia chromosome translocation. The normal chromosomes 9 
and 22 carry the c-ABL and c-BCR genes, respectively. The translocation results in the formation 
of a shortened chromosome 22 (the Philadelphia chromosome) carrying the BCR–ABL fusion gene. 
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2.1.1 Clinical characterization of CML 
 
The course of the disease is characteristically triphasic: a chronic phase (CP) 
lasting three to six years is followed by transformation to an accelerated phase 
(AP) and then a terminal blast phase (BP) of short duration (Faderl et al., 1999). 
Chronic phase is characterized by an expansion of immature and mature myeloid 
cells and retention of hematopoietic differentiation (Lichtman MA., 1995). 
Patients initially are asymptomatic but also show fatigue, splenomegaly, anemia 
and high white blood cell counts in the peripheral blood. Both accelerated and 
blast phases are characterized by a severe reduction in cellular differentiation, 
with a replacement of mature cells by immature blasts (Lichtman MA., 1995) at 
this point patients have more severe clinical symptoms including those related to 
infectious and bleeding complications. Blast crisis essentially resembles acute 
leukemia which can either be of lymphatic (30%), or more frequently of myeloid 
character (approx. 70%). 
2.1.2 Structure of the BCR and ABL 
 
The N-terminus of BCR-ABL kinase contains the "Cap" region, which is present 
in 2 different isoforms generated by alternative splicing of the first exon, termed 
1a and 1b. ABL 1b contains a C14 myristoyl moiety (myristoylation is a process 
that attaches the fourteen-carbon saturated fatty acid myristate to the amino-
terminal glycine of proteins) covalently linked to the N terminus. ABL also 
contains a tyrosine kinase domain preceded by highly conserved Src-homology-2 
(SH2) and SH3 domains (Hantschel and Superti-Furga, 2004). The last exon 
region contains 4 proline-rich SH3 motifs that function as binding sites for adaptor 
proteins such as Crk, GRB2 (growth-factor-receptor-bound 2), and Nck, (Feller et 
al., 1994; Smith et al., 1999) a DNA-binding domain, an actin-binding domain, 3 
nuclear localization signals (NLS), and 1 nuclear export signal (NES), which 
determines ABL subcellular localization in response to environmental stimuli 
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(Quintas-Cardama and Cortes, 2009). The carboxy terminal contains DNA as well 
as G and F actin binding domains. 
BCR contains a coiled-coil dimerization domain (DD), a serine/threonine kinase 
domain, a Dbl/CDC24 guanine-nucleotide exchange factor (RHO-GEF) homology 
domain, a pleckstrin homology domain (PH), a putative calcium-dependent lipid 
binding site (CaLB), and a Ras-related C3 botulinum toxin substrate (RAC) 
guanosine triphosphatase–activating protein domain (Rac-GAP). Tyr177 at BCR 
serves as docking site for GRB2, GRB10 and the ABL proteins through its SH2 
domain (Ren, 2005).  
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Figure 2: Structure of BCR and ABL protein.  (A) Type 1b isoform of ABL protein is 
slightly longer than 1a because of myristoylation (myr) site for attachment to the plasma 
membrane. 3 SRC-homology (SH) domains situated toward the NH2 terminus. The major site of 
auto-phosphorylation within the kinase domain is Y393. Phenylalanine 401 (F401) is highly 
conserved in phospho tyrosine kinase (PTKs) containing SH3 domains. Phosphorylation sites by 
Atm, cdc2, and PKC are shown. The arrowhead indicates the position of the breakpoint in the 
BCR-ABL fusion protein. (B) At N terminus BCR contains dimerization domain and 2 cyclic 
adenosine mono phosphate kinase homologous domain. Y177 is the autophosphorylation site 
crucial for binding to Grb-2. 
 
2.1.3 Molecular anatomy of BCR ABL translocation 
 
3 
 
Introduction 
The ABL gene encodes a ubiquitously expressed, non-receptor tyrosine kinase 
with a molecular mass of 145 kD (p145
ABL
). The ABL gene contains 11 exons 
among which the first exon has two variants: 1a and 1b, derive from alternative 
splicing of the first exon (Kurzrock et al., 1988). The breakpoint in the ABL gene 
may occur anywhere over a large 300 kb area at its 5’ end, either downstream of 
exon 1a or upstream of exon 1b, between the two. The ABL exons 2 to 11 (also 
called a2 to a11) are juxtaposed to the 5’ part of BCR. The major breakpoint 
cluster region (M-bcr) of the BCR gene on chromosome 22 is located between 
exon 12 and 16 (referred to as b1 to b5) and extends over 5.8 kb. 
Ib                                      Ia        a2 a3        a11 
e1              e1’e2’ b2 b3   e19     
Minor breakpoint 
cluster region (m-bcr)
Major breakpoint 
cluster region (M-bcr)
µ-bcr
b2a2
or
b3a2
ABL
BCR
BCR-ABL
 
 
Figure 3: Schematic representation of chimeric bcr-abl mRNA generation. The 
location of breakpoints during translocation of chromosomes 9q and 22q leading to the generation 
of the Philadelphia chromosome carrying the BCR-ABL fusion gene. Exons are shown as boxes 
(brown for ABL, red for BCR) and breakpoints are indicated by arrows. In most cases of CML, 
breakpoints occur within the BCR gene at 22q11 within a 5.8kb sequence spanning exons b1-b5 
known as major breakpoint cluster region (M-bcr). Breakpoints within the ABL gene at 9q35 occur 
in a region of about 30kb at 5’ end of the ABL gene, either upstream of the first alternative exon 
1b, downstream of the second alternative exon 1a or more frequently between the two. All of these 
possible breakpoints and subsequent chromosomal translocations result in production of an mRNA 
where BCR sequences (exon b2 or b3) are fused to ABL exon a2, as a result of the splicing of the 
primary hybrid transcript leading to generation of different fusion transcripts (b2a2, b3a2).  
Two fusion transcripts b2a2 and b3a2 are created, and both translate into a 
chimeric protein of 210 kD named p210
BCR-ABL
 (Kurzrock et al., 1988) (Figure3). 
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In 95% of BCR-ABL positive CML, the leukemic cells have either b2a2 or b3a2 
transcripts, but in 5 percent of cases, alternative splicing events cause the 
expression of both fusion products (Melo, 1996)  
2.2 Signaling pathways of BCR-ABL  
 
BCR-ABL
 
allows multiple protein-protein interactions which involves diverse 
intracellular signaling pathways. Several domains in BCR-ABL serve to bind  
 
 
ICSBP
ICSBP
P
STAT 5
BCL-X
Bcl2
STAT 5
HCK/LYN
P
Proliferation 
??
Nucleus
Cytoplasm
 
 
Figure 4: BCR-ABL-dependent signaling pathways. modified from (Weisberg et al., 
2007a; Weisberg et al., 2007b) 
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adapter proteins such as growth factor receptor-bound protein 2 (GRB2), CRK-
like protein (CRKL), casitas B-lineage lymphoma pro-oncogene protein (CBL), 
and SRC homology 2-containing protein (SHC) (Puil et al., 1994). The SH2 
domain of GRB2 binds to a conserved tyrosine residue (Y177) of BCR in 
p210
BCR-ABL
, which links p210
BCR-ABL 
to RAS, a guanosine triphosphate (GTP) – 
binding protein involved in the regulation of cell proliferation and differentiation 
and located at the core of the most prominent signaling pathway in the 
pathogenesis of CML (Sawyers et al., 1995)  (Figure 4) 
Signaling events downstream of RAS are not well characterized and may involve 
mitogen-activated protein kinases (MAPKs), such as the JUN kinase (JUK) 
(Raitano et al., 1995). Activation of the CRKL or SHC protein which bind to the 
SH2 and SH3 domains of BCR-ABL, respectively, can also initiate signal 
transduction of the RAS signaling pathway (Oda et al., 1994; Senechal et al., 
1996). Signal transducer and activator of transcription 5 (STAT5) of the 
JAK/STAT5 pathway can be phosphorylated directly by BCR-ABL, independent 
of the RAS signaling pathway (Chai et al., 1997; Ilaria and Van Etten, 1996), 
which leads to the up-regulation of the anti-apoptotic protein BCL-XL which is  
repressed by transcription factor interferon consensus sequence binding protein 
(ICSBP). BCR-ABL abrogates transcription of ICSBP through an unknown 
mechanism which releases ICSBP mediated inhibition of BCL-2 and BCL-X gene 
transcription and results in increased survival of myeloid progenitor (Burchert et 
al., 2004). Furthermore,  phosphatidylinositol-3 kinase (PI-3K) pathway is 
activated by BCR-ABL, which results in enhanced pro-mitogenic and anti-
apoptotic signals (Skorski et al., 1995). C-Myc has also been identified to be 
involved in the BCR-ABL signaling pathway (Afar et al., 1994).   
Although the different signaling pathways of BCR-ABL have been intensively 
studied, none has been identified to explain all phenotypic features described in 
CML. However, as an end result, the uncontrolled kinase activity of BCR-ABL 
gives rise to deregulated cell proliferation, decreased adherence of leukemic cells 
to the bone marrow stroma, and inhibition of apoptosis. 
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2.3 Therapy for CML 
2.3.1 First generation of Tyrosine kinase inhibitor IM 
 
Initial treatment modalities of CML include cytotoxic chemotherapies such as 
busulfan and hydroxyurea. Later stem cell transplantation and interferon α therapy 
have already offered the possibility of complete and durable cytogenetic responses 
(Talpaz et al., 1991). However, IM was developed as the first molecularly targeted 
therapy to specifically inhibit the BCR-ABL tyrosine kinase in Philadelphia 
chromosome positive CML (mechanism of action in figure 5). Because of the 
excellent hematologic and cytogenetic responses, IM has moved toward first-line 
treatment for newly diagnosed CML. However, emergence of resistance and 
persistence of BCR-ABL positive cells (residual disease) after therapy are two 
major obstacles to IM based therapies for patients with CML. 
       
Figure 5: Mechanism of action of IM. The active site of the BCR-ABL tyrosine kinase 
has an ATP binding site. BCR-ABL phosphorylates its substrate by transfer of the terminal 
phosphate from ATP to tyrosine residues on its substrates. IM works by binding to the ATP 
binding site of BCR-ABL and inhibiting the enzyme activity of the protein competitively. 
2.3.2 Second generation of tyrosine kinase inhibitor 
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Dasatinib 
Dasatinib inhibits number of kinases, including BCR-ABL, src family, c-Kit, 
EPHA2 and PDGFRβ  (Lombardo et al., 2004; Schittenhelm et al., 2006) 
Dasatinib is approximately 325 fold more potent against BCR-ABL inhibition 
(O'Hare et al., 2005) than IM and can bind to both active and inactive 
conformations of the ABL kinase domain. Dasatinib has been shown to inhibit 18 
out of 19 BCR-ABL mutations mediating resistance to IM in-vitro (O'Hare et al., 
2005; Schittenhelm et al., 2006; Shah et al., 2006). Dasatinib has activity against 
many IM resistance-inducing  kinase domain mutations of BCR-ABL, including 
those within the phosphate-binding loop (P-loop) and those within the activation 
loop and other sites in the COOH-terminal loop (O'Hare et al., 2005; Talpaz et al., 
2006; Tokarski et al., 2006). Dasatinib may overcome resistance mechanisms of 
IM, including alternate signaling pathways involving the Src family kinases and 
MDR-1 gene overexpression (Thomas et al., 2004). Most of the clinically relevant 
mutations are inhibited by Dasatinib with the exception of the T315I mutation, 
which confers resistance to IM, dasatinib, and nilotinib (O'Hare et al., 2005; 
Tokarski et al., 2006) 
 
Nilotinib 
Nilotinib (AMN 107) is another orally available second-generation kinase 
inhibitor of BCR-ABL, KIT, PDGFR and ephrin receptor kinase. Nilotinib is an 
analog of IM and it disrupts the ATP-phosphate-binding pocket of the ABL 
tyrosine kinase and inhibits enzymatic catalytic activity by binding to the inactive 
conformation of the enzyme, blocking the substrate binding site. Similar to 
dasatinib, nilotinib has no activity against the T315I mutation but was able to 
overcome resistance in 32 of 33 IM resistant BCR-ABL mutations. 
 
2.4 Mechanisms of resistance to IM 
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2.4.1 BCR-ABL independent mechanisms of resistance 
 
Intracellular uptake of IM depends on the net result of between influx and efflux 
of the drug into the cell. The adenosine triphosphate-binding cassette (ABC) 
transporter ABCB1 (or MDR-1), for example is a transmembrane protein that 
mediates multidrug resistance through induction of increased efflux of different 
chemotherapeutic agents. Overexpression of ABCB1 is also a possible mechanism 
for resistance to IM, it was first reported by Mahon and colleagues in cells from 
patients with BP CML (Mahon et al., 2000). Alternatively, inhibition of IM uptake 
into the cell has been proposed through the human organic cation transporter 
(hOCT1) and was shown as an important factor regulating intracellular IM 
availability (Crossman et al., 2005; Thomas et al., 2004).  
 
IM resistance may also result from the acquisition of additional nonrandom 
cytogenetic aberrancies in Philadelphia positives metaphases, also referred as 
“clonal evolution”. Clonal evolution has been observed more frequently in 
patients in progressed phase of CML. The most frequent cytogenetic 
abnormalities associated with clonal evolution are trisomy 8 (34%), 
isochromosome 17 (20%), and duplicate Ph chromosome (38%) (Johansson et al., 
2002) which have been linked to c-Myc over expression, loss of 17p, and BCR-
ABL over expression, respectively (Haferlach et al.). 
 
2.4.2 BCR-ABL Dependent mechanism of Resistance 
BCR-ABL Overexpression: Upregulation of the BCR-ABL kinase in association 
with amplification of the BCR-ABL gene was first reported in the Ba/F3 BCR-
ABL-r, LAMA84-r, and AR230-r IM-resistant cell lines in the absence of 
mutations within the BCR-ABL kinase domain (Hochhaus et al., 2002; le Coutre et 
al., 2000). CD 34+ CML cells expressing high amount of BCR-ABL are much less 
sensitive to IM, but yield mutant, IM resistant subclones and develop mutations 
much faster than those with low level of BCR-ABL expression  (Barnes et al., 
2005).  
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Point mutation in the kinase domain of BCR-ABL: Point mutations cause 
amino acid substitutions inside the kinase domain of the BCR-ABL protein and 
disrupt the binding site of IM on the tyrosine kinase, resulting in a loss of 
sensitivity to the drug. Mutations can either directly interrupt critical contact 
points between the drug and the BCR-ABL protein or induce a conformational 
change, resulting in a protein that is unable to bind IM (Branford et al., 2003b; 
Hochhaus et al., 2001). There more than 40 point mutations known to occur 
within the ABL kinase and these may lead to secondary or acquired resistance 
after IM treatment (Gorre et al., 2001; Weisberg et al., 2006). The first reported 
mutation mediating resistance was T315I which represents the replacement of a 
threonine by an isoleucine at amino acid position 315 in the ABL component of 
the kinase (Gorre et al., 2001). To date, more than 50 different BCR-ABL kinase 
domain mutations have been found to be associated with IM resistance (Branford 
et al., 2003a; Branford et al., 2002; Shah et al., 2002). BCR-ABL kinase mutations 
cluster into four main groups. The first group (G250E, Q252H, Y253F and 
E255K) includes the corresponding amino acids in the nucleotide-binding loop for 
ATP, also known as the p-loop mutations (Hochhaus et al., 2001; von Bubnoff et 
al., 2002). The second group of mutations is localized in the IM-binding site and 
directly interacts with the drug via a hydrogen bond (T315I) and Van der Waals’ 
interactions (V289A, T315I and F317L) (Branford et al., 2002; Gorre et al., 2001). 
The third group of mutations (M388L and H396P) is found in the activation loop 
(A-loop) (von Bubnoff et al., 2002). These mutations result in a preferred 
transition of the protein from an inactive conformation to an active conformation 
to which IM can not bind (Schindler et al., 2000). The fourth group includes 
amino acids distant from the IM binding site (Branford et al., 2002; Shah et al., 
2002), which form a hydrophobic patch between helices E, F and I in the C-
terminal lobe of the enzyme, highly conserved region within the tyrosine kinase 
family (Hubbard, 1997). Despite their different locations, some mutations, such as 
T315I are completely or near completely insensitive to IM and the second-
generation TKIs dasatinib, nilotinib, and bosutinib at clinically achievable doses. 
10 
 
Introduction 
 
2.5 Leukemic stem cell model 
 
Most leukemia types initially respond well to therapy with partial or even 
complete remission. However, after a period of minimal residual disease many 
patients succumb to refractory relapses of the disease. According to stem cell 
model of leukemia relapse of the disease is due to the selective continued survival 
of a small, but distinct population of therapy-resistant tumor-initiating cells, 
commonly referred to as leukemic stem cells (LSC) or CML stem cell (CSC)  
(Bonnet and Dick, 1997; Lapidot et al., 1994). Interestingly, these CSC, which 
initially coexist with normal HSCs, have a selective disadvantage in reconstituting 
NOD-scid mice transplanted with bone marrow or peripheral blood from patients 
with early phase CML (El-Ouriaghli et al., 2003; Sirard et al., 1996; Verstegen et 
al., 1999; Wang et al., 1998). Progression to BP CML requires either the 
expansion of LSC or the acquisition of self renewal property by a subset of 
committed progenitors. In a mouse model, expression of the hMRP8 p210BCR-ABL 
transgene targeted to GMP and their myelomonocytic progeny, but not to HSC, 
renders a phenotype that resembles human CML, including progression to AP and 
BP (Jaiswal et al., 2003). These data suggest that BP may result from the 
progressive acquisition of genetic alteration within progenitor downstream of CSC 
that acquires self renewal or “stemness” property.  A comparison of the gene 
signatures of chronic accelerated, and blast phases suggest that the progression of 
CML is a two-step process, which includes deregulation of the WNT/β-catenin 
pathway, the decreased expression of Jun B and Fos, alternative kinase 
deregulation, such as Arg (Abl2), and an increased expression of PRAME (Radich 
et al., 2006). Thus hypothetically, CML could be considered as stem cell derived 
but progenitor driven disorder. 
LSC absolutely require self-renewal capability to propagate the disease. Wnt 
signaling pathway  plays an important role in regulating stem cell self-renewal 
(Taipale and Beachy, 2001).  Stabilized β-catenin (a downstream activator of the 
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Wnt signaling pathway) has been shown to promote the self-renewal of stem cells 
and other types of progenitor cells (Reya et al., 2001; Zhu and Watt, 1999). 
Mutations in other signaling pathways that promote progenitor self-renewal, such 
as Notch and Shh, also contribute to unregulated self-renewal of LSC (Bhardwaj 
et al., 2001; Varnum-Finney et al., 2000).  
 
2.6 Disease persistence  
 
IM has become the standard front-line therapy for CML by inhibiting BCR-ABL 
positive leukemic cells. However, despite long-term IM therapy, BCR-ABL 
positive cells remain detectable during complete cytogenetic remissions (CCR)  
(Druker et al., 2006; Hughes et al., 2003). Minimal residual disease is almost 
always detectable and known as disease persistence (Bhatia et al., 2003). 
Further studies have demonstrated that IM effectively eradicates Bcr-Abl-positive 
progenitor cells, but does not target Bcr-Abl-positive CD34+ LSCs (Graham et al., 
2002; Jiang et al., 2007). While new inhibitors (nilotinib and dasatinib) that target 
primary IM-resistant Abl mutants provide treatment options for relapsed patients 
or patients in blast-crisis CML, these Abl inhibitors also do not target the LSCs in 
CML. CML persistence supposedly results from an inherent insensitivity to IM of 
the CML stem and progenitor cells (Copland et al., 2006; Graham et al., 2002; 
Jorgensen et al., 2007). Stem cell persistence is also supported by clinical 
evidence showing that IM discontinuation at the time of stable complete 
molecular remission (CMR) may still result in hematological relapse (Breccia et 
al., 2006; Cortes et al., 2004; Guastafierro et al., 2009; Rousselot et al., 2007). 
Various mechanisms may account for CML persistence under IM. These include, 
for example, BCR-ABL overexpression (Copland et al., 2006; Jiang et al., 2007a; 
Jiang et al., 2007b), drug in- and efflux mechanisms (Brendel et al., 2007; Engler 
et al., ; Thomas et al., 2004), and Abl-kinase point mutations (Chu et al., 2005). 
On the other hand, the number of patients with undetectable BCR-ABL transcripts 
rises with longer IM treatment duration, and approached 52% after 5 years in a 
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sub-cohort of the IRIS study (Branford et al., 2007). These clinical results are 
clearly intriguing in view of the current model that CML precursors and HSC are 
essentially IM-insensitive.  
 
2.7 Interferon consensus sequence binding protein (ICSBP) 
Interferon consensus sequences binding protein (ICSBP), also known as IFN 
regulatory factor-8 (IRF-8) is a transcription factor of Interferon regulatory factor 
(IRF) family.  IRF family consists of nine cellular transcription factors which 
share a high homology within the N-terminal at first 115 amino acids. This part 
comprises the DNA-binding domain (DBD) and therefore binds to the similar 
DNA element known as interferon stimulated response element (ISRE). ISRE 
contains the IRF recognition sequence (IRS) AANNGAAA, to which IRF family 
binds. These IRFs mediate several biological activities such as anti-viral immune 
response, proliferation, and hematopoietic differentiation (Cohen et al., 2000).  
ICSBP is constitutively expressed in B cells and monocyte cells, and, at low 
levels, in resting T cells. Its expression can be further induced by IFN-γ, by 
combined exposure of macrophages to IFN- γ and lipopolysaccharide (LPS) and 
by antigenic stimulation of T cells (Barber et al., 1995; Driggers et al., 1990; 
Nelson et al., 1996; Nelson et al., 1993; Politis et al., 1994; Weisz et al., 1994; 
Weisz et al., 1992). IFN- alpha also can induce ICSBP gene expression in vivo 
(Schmidt et al., 1998). ICSBP can selectively suppress the expression of some 
interferon responsive genes, such as major histocompatibility complex type 1 
genes, and activates others, such as interleukin-12 (IL-12) gene. The DNA binding 
ability of ICSBP is very weak but dramatically increased by interaction with IRF 
1 and IRF 2 (Bovolenta et al., 1994; Sharf et al., 1997). The interaction is 
mediated by the IRF association domain, which is conserved among several IRF 
members. ICSBP also binds to the Ets family transcription factor PU.1, which is 
required for development along the lymphoid and myeloid lineages of the cells. 
13 
 
Introduction 
2.7.1 Structure of ICSBP 
ICSBP, a 50-kD protein, contains a DNA binding domain (DBD) which consists 
of a repeat of five conserved tryptophans (w) each separated by 10 to 18 amino 
acid residue (Harada et al, 1989). DBD is localized at N terminus and followed by 
IRF association domain (IAD).  
      
w  w  w  w  w  w IAD
DNA binding domain                       IRF interaction domain
1                                     121              200      377         424aa
 
Figure 6: Structure of ICSBP protein.  
Furthermore, the IAD is essential for the association of ISGF3 /IRF-9, a non-
tissue-restricted IRF member, with Stat1 and Stat2 to form the ISGF3 complex, 
which plays a pivotal role in IFN type I signaling (Veals et al., 1993). This 
suggests that IRFs-IAD modules are spatially organized like a key lock 
mechanism. This means, the overall structure is similar and determined by 
conserved residues, while non-conserved residues dictate the specificity of 
interactions. A point mutation within IRFs-IAD in a conserved leucine to proline 
(Leu331 in ICSBP-IAD) was able to ablate the interactions of ICSBP with IRF-1, 
IRF-2, PU.1, and E47, the interaction of IRF-4 with PU.1 and E47 (Meraro et al., 
1999) and the interaction of ISGF3  with Stat1 and Stat2.  ICSBP is 
transcriptional repressor acting through the IFN stimulated response element 
(ISRE). ISRE and IFN consensus sequences (ICS) contain the IRF recognition 
sequence (IRS) AANNGAAA, to which the DBD of the IRF family binds.  
2.7.2 ICSBP in chronic myeloid leukemia 
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ICSBP plays an important role in regulating immune responses and 
hematopoiesis. Interestingly, ICSBP-deficient mice manifest a CML-like 
syndrome characterized by enhanced proliferation of myeloid, monocytic and 
lymphoid lineage, suggesting role for ICSBP in regulating the proliferation and 
differentiation of hematopoietic progenitor cells. Transition of the chronic phase 
to a fatal blast crisis is a characteristic feature of human  CML. Approximately 
33% of  ICSBP-/- and 9% of ICSBP+/- mice died by 50 weeks of age, with 
features indicating a transition to a blast crisis (Holtschke et al., 1996). It has been 
reported that ICSBP expression is decreased in CML patients and this reduction of 
ICSBP transcripts could be reversed by IFN-α treatment (Schmidt et al., 1998).  
Forced expression of  ICSBP induces potent immunity against BCR-ABL induced 
leukemia in mice (Deng and Daley, 2001). Furthermore, ICSBP also functions as 
a tumor suppressor and regulator of apoptosis (Gabriele et al., 1999; Schwieger et 
al., 2002). ICSBP mediates its anti-oncogenic effects by down-regulating bcl-2 
(one of the key anti-apoptotic cancer genes) because it is essentially required for 
BCR-ABL induced transformation, apoptosis, and drug resistance (Burchert et al., 
2004). These data suggest that ICSBP plays an important role in the development 
of malignant myeloid leukemia and regulation of apoptosis.  
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                                                                                                            Aim of Project 
3 AIM OF THE PROJECT 
 
1. To identify the mechanism of disease persistence in CML patients treated with 
IM.  
Treatment with the Abl-kinase specific inhibitor IM is very effective in chronic 
myeloid leukemia. However, IM presumably fails to eradicate CML stem cells 
leading to disease persistence and relapse after IM-discontinuation. Although 
causes of CML persistence under IM remain ill defined, quiescence and BCR-
ABL overexpression of CML stem and progenitor cells have been suggested as 
underlying mechanisms. The aim of this study was to track residual disease in 
different bone marrow fractions of patients in MMR in order to subsequently 
genetically analyse individual persisting clones. 
2. To identify the role of ICSBP deficiency in BCR-ABL induced transformation 
and emergence of resistance to IM.  
Even after recent therapeutic strategies in CML, resistance and persistence of 
leukemic (stem) cells under TKI therapy still remains a significant clinical 
problem. Mutations in ABL kinase domain account for TKI-resistance in about 
90% of BCR-ABL positive ALL, but only in ~30% of CML patients. Still little is 
known about mutation-independent mechanisms of TKI resistance and the nature 
of kinase mutation emergence. However ICSBP is known to induce apoptosis in 
BCR-ABL transformed cells. Here, we aim to elucidate whether apoptosis 
sensitivity, of BCR-ABL transformed cells, induced by ICSBP linked to point 
mutation development as a major IM resistance mechanism.  
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4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Chemicals 
 
Chemicals  Source 
Acrylamide/Bis-acrylamide Roth 
Agar Carl Roth 
Agarose    Gibco-BRL, 
Ammoniumperoxodisulfat (APS) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
β-mercaptoethanol Carl Roth 
Bovine serum albumin (BSA) Sigma-Aldrich 
Bromophenol blue  Serva 
Calcium chloride    Merck 
Chloroquin Sigma-Aldrich 
Complete protease inhibitor  Roche 
Dimethyl sulfoxide (DMSO) Merck 
1,4-Dithiothreitol Roth 
d NTPs Invitrogen 
Ethanol Carl Roth 
Ethidium Bromide Sigma-Aldrich 
17
17 
 
Materials and Methods 
Ethylene diaminetetraacetic acid disodium salt (EDTA) Merck 
Ficoll-PagueTM PLUS Amersham Biosciences
Formaldehyde Carl Roth 
Gene Ruler™ 100bp ladder MBI Fermentas 
Glycerol Merck, Darmstadt 
Glycine Sigma-Aldrich 
Hydrochloric acid Merck 
Hydrocortisone Stem Cell Technology 
Igepal CA-630 (indistinguishable from NP-40) Sigma-Aldrich 
IM mesylate  Novartis Pharma 
Isopropanol Carl Roth 
LB Agar Invitrogen 
LB Broth Base 
L-Glutamine 
Invitrogen 
Gibco BRL 
Methanol Merck 
Milk powder Merck 
N-Ethyl-N-Nitrosurea Sigma- Aldrich 
Orthovanadate Sigma- Aldrich 
Ouabain  Sigma- Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) 
Polybrene (Hexadimethrin Bromide) 
Sigma-Aldrich 
Sigma- Aldrich 
18
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Ploy-L-Lysine Sigma- Aldrich 
Propidium iodide(PI) 
Retronectin 
Sodium Butyrate 
Sigma- Aldrich  
Takara 
Upstate 
Sodium chloride Sigma-Aldrich 
Sodium dodecyl sulfate (SDS) Merck 
Sodium hydroxide Merck 
Sodium Orthovanadate Sigma- Aldrich 
N,N,N´,N´-Tetramethylethylenediamine (TEMED) Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane (Tris) Roth 
Tween®20 Roth 19
 
4.1.2 Cell Culture Media, cytokines and Antibiotics  
 
Reagent  Source 
RPMI 1640 medium  (72400-021) Gibco-BRL 
IMDM medium (SH30228.01) HyClone® HyClone 
DMEM medium  (41965) Gibco-BRL 
X-vivo medium Lonza Biowittekar 
MethoCult H4330 
MethoCult H5100 
Stem Cell Technologies 
Stem Cell Technologies 
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Collagen Solution Stem Cell Technologies 
Ampicillin Sigma-Aldrich 
Penicillin/Streptomycin (15140-114) Biochrom KG 
Hygromycin B Roche 
Puromycin Sigma- Aldrich 
Blasticidin Sigma- Aldrich 
G418 sulphate PAA 
BSA Stem cell technology 
Fetal calf serum (FCS) Gibco-BRL 
Trypsin Gibco-BRL 
Recombinant mouse IL3 Immuno tools 
Recombinant mouse IL6 Immuno tools 
Recombinant mouse SCF Immuno tools 
20
 
4.1.3 Equipment 
 
Hardware Manufacturer 
Autoclave Stiefenhofe 
Agarose gel electrophoresis chambers BioRad 
Bacterial shaker Innova, New Brunswic 
Scientific 
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Balance machine Kobe 
Electrophoresis power supply Pharmacia Fine Chemicals 
ELISA reader Labsystems Multiskan RC 
FACS SCAN Becton Dickinson 
Gel camera PeqLab Biotechnologie GmbH 
GeneAmp® PCR system 9600 Applied Bioystems,  
Heating blocks Eppendorf 
PCR machine Eppendorf  
pH meter Fisher Scientific 
Ice machines Genheimer 
Inverted microscope (DMIL) Leica, Wetzlar 
Laminar hoods Heraeus 
Liquid nitrogen tank Tec-Lab 
Micro liter pipettes 
MoFlo 
Gilson 
Dako Cytomation 
OPTIMAX® film processor PROTEC processorTechnology 
Power supply units (MODE/250EX) Gibco BRL  
Semi-dry blot apparatus BioRad, München 
Sequence detection system (ABI PRISM 7700) PE Applied-Biosystems 
Water bath Unitherm 
X-ray film processor (UVT 2035) Herolab 
21
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4.1.4 Kits 
 
Kit Source 
BCA Protein Assay Kit Prerce 
cDNA Synthesis Kit Invitrogen 
Gel extraction Kit Qiagen 
MACS separation Kit Milteney Biotech 
Plasmid Mini prep Kit Qiagen 
Plasmid Maxi prep Kit  Qiagen 
RNA isolation Kit Qiagen 
Lineage Cell Depletion Kit, Mouse Miltenyi Biotech 
BCR-ABL Mbcr FusionQuant Kit Ipsogen 
22
 
4.1.5 Miscellaneous 
 
Cryotubes Greiner bio-one 
Disposable needles, cuvettes & syringes Greiner bio-one 
DNA and protein size markers 
Glasswares 
Fermentas 
Schott 
Nitrocellulose membrane Amersham Life Science 
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Polypropylene tubes Greiner bio-one 
Parafilm Greiner bio-one 
Pipette tips Greiner bio-one 
Röntgen film (13x18 cm, BioMax) Kodak 
Tissue culture plates Greiner bio-one 
Tissue culture flask (T-25, T-75 & T-250) Greiner bio-one 
Tissue culture dish (60 mm, 90 mm) Greiner bio-one 
Tubes (1.5 and 2 ml)  Eppendorf 
Whatmann paper  Schleicher & Schuell 
6,12 and 24 well cell culture plates  Cellstar 
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4.1.6 Cell Lines 
 
List of the cell lines used in the study 
1. 32D cells (murine mayeloid cell line) 
2. M210B4 cells (murine stroma cell line)  
3. K562 cells (Human erythromyeloblastoid leukemia cell line) 
4. U937 cells (Human leukemic monocyte lymphoma cell line) 
5. Phoneix cells (human embryonic kidney cell line) 
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4.1.7 Stable cell lines generated during study: 
 
1 .32D BCR/ABL 
2. 32D-MIGR1 (control vector) 
2. 32D BCR/ABL- ICSBP 
3. 32D BCR/ABL-Bcl2 
4. 32D BCR/ABL-ICSBP-Bcl2 
5. 32D-ICSBP-GFP 
6. 32D-pSF91 (Control vector ) 
4.1.8 Plasmid and construct 
 24
MIGR1- BCR ABL (p210) 
MIGR1 (control plasmid) 
pSF91 –eGFP- PRE (control plasmid) 
pSF91 –ICSBP –eGFP- PRE (cloned during study) 
pMY-mAID-IRES-EGFP 
pMY-IRES-EGFP (control plasmid) 
pBABE puro-Bcl-2 
pBABE puro (control plasmid) 
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4.1.9 PCR Primer sequence for cDNA: 
h-ICSBP  5’ GTC CCA ACT GGA CAT TTC CG 3’ 
 5’CAT TCA CGC AGC CAG CAG -3’ 
h-GAPDH  5’CTC CTC CAC CTT TGA CGC TG 3’ 
 5’ ACC ACC CTG TTG CTG TAG CC 3’ 
h-Actin  5’CCT TCC TGG GCA TGG AGT CCT 3’ 
 5’AAT CTC ATC TTG TTT TCT GCG 3’ 
Bcr/abl  5’TTC AGA AGC TTC TCC CTG ACA TCC GT 3’ 
 5’GGT ACC AGG AGT GTT TCT CCA GAC TG 3’ 
Bcr/abl (nested) 5’GTC CAC AGC ATT CCG CTG ACC ATC AAT -3’ 
 5’TGT TGA CTG GCG TGA TGT AGT TGC TTG G 3’ 
m-P21 5’GCC ACA GAA TTC ATG TCC AAT CCT GGT GAT  
 5’GCT CCC GTC GAC GGC ACT TCA GGG TTT TCT 3’ 
m-AID 5’AAA TGT CCG CTG GGC CAA 3’ 
 5’CAT CGA CTT CGT ACA AGG 3’ 
m-PUMA 5’GCC CAG CAG CAC TTA GAG TC 3’ 
 5’TGT CGA TGC TGC TCT TCT TG 3’ 
m-MDM 2 5’TGC AAG CAC CTC ACA GAT TC 3’ 
 5’ACA CAA TGT GCT GCT GCT TC 3’ 
m-GAPDH  5’CAT GGC CTT CCG TGT TCC TA 3’ 
 5’CCT GCT TCA CCA CCT TCT TGA 3’ 
25
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m-ICSBP 5’AGA GGG AGA CAA AGC TGA ACC 3’ 
 5’TGA ATG GTG TGT GTC ATA GGC  3’ 
m-MGMT 5’AAG CTG GAA CTT GGC AGA AT 3’ 
 5’ACT GAG CAA CCG TAT CCC AT 3’ 
m-HUS1 5’TTT GCT TAC CAG CCT TGA AGA 3’ 
 5’CCC TTT AGG TTG GCT TCA ATC 3’ 
m-LIG 1 5’ACA TCT CCC CAT CAG GAT TC 3’ 
 5’TGT CCT CAT TCT GCT CCT CA 3’ 
m-XRCC 2 5’GAT GTG TAG CGA CTT TCG CA 3’ 
 5’ATC AGC AAA CAG GTT GGG TT 3’ 
m-CHK 1 5’GGG GTG GTT TAT CTT CAT GG 3’ 
 5’GCC AAG CCA AAG TCA GAG AT 3’ 
m-OGG 1 5’TAT CAT GGC TTC CCA AAC CT 3’ 
 5’TGG CAC TGG CAC GTA CAT AG 3’ 
m-PARP-2 5’AAG CTG GGA AAG GCT CAT GT 3’ 
 5’CTT GTT GTT GTT GAA CTG GAG A 3’ 
m-MDB 4 5’ACA GGA TGG CTC  TGA AAT GC 3’ 
 5’CTA CTT GTG TCC GTG GGA TG 3’ 
m-MPG 5’CCG GCT AGG ACC AGA GTT TT 3’  
 5’CCA CGG AGT TCT GTT CCA TC 3’ 
m-TLK1 5’AGG TCC CTG CTG AAT CAC AC 3’ 
26
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 5’ TTC TTG CCT TCT TGG GTC C 3’ 
m-PMS-2 5’ CCC TAG TGA CGC TGT GTG TG 3’ 
 5’ CGT GCA CTG TGA AAT GAA GC 3’ 
m-POLD-3 5’ TTC ATG TTA ACC AGG CCA AA 3’ 
 5’ GAC TGC CAG ACA CCA AGT AGG 3’ 
m-MUTYH 5’ AGA ACA CGT GCC CTT AGC AG 3’ 
 5’ TGA TAT GGG GAG ACA GAG GC 3’ 
 
4.1.10 Antibodies for western blot 
cABl (24-11) Santacruz Biotechnology 
p-CrkL (3181L) Cell Signaling 
p-STAT 5 (8-5-2) Upstat 
β-Actin Sigma 
Bcl 2 (7/Bcl2) Transduction lab 
p-Akt Cell Signaling 
Akt (H-136) Santacruz Biotechnology 
ICSBP(C 19) Santacruz Biotechnology 
CrkL (C-20) Santacruz Biotechnology 
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4.1.11 Antibodies for FACS analysis: 
Antibodies Source 
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CD2 – FITC (S5.2), Human BD Biosciences 
CD3- FITC (HIT3a), Human BD Biosciences 
CD4- FITC (RPA-T4), Human BD Biosciences 
CD8 – FITC (HIT8a), Human BD Biosciences 
CD14  - FITC (MΦP9), Human BD Biosciences 
CD19  - FITC (ID-3), Human BD Biosciences 
CD20- FITC, Human BD Biosciences 
CD56, Human BD Biosciences 
GPA, Human BD Biosciences 
CD34- PE Cy 7 (8G12), Human BD Biosciences 
CD 38 PerCP-Cy5.5 (HIT2), Human BD Biosciences 
CD123 PE (9F5), Human BD Biosciences 
CD45RA- APC (HI100), Human BD Biosciences 
CD 34- PE (RAM34), Mouse eBioscience 
Sca1- Pacific blue (E13-161.7), Mouse Biolegend 
c-Kit- APC (2B8), Mouse eBioscience 
FcγR- PE-Cy (93), Mouse eBioscience 
Lineage Biotin Antibody Cocktail 
mouse 
Miltenyi Biotech 
Anti –Biotin MicroBeads  Miltenyi Biotech 
CD 34 MicroBeads, human Miltenyi Biotech 
28
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FcR Blocking Reagent  Miltenyi Biotech 
Annexin V- FITC  
 
4.1.12 Mice 
 
6 to 8 weeks old pathogen-free C57 Black6 mice and ICSBP knock out mice were 
obtained from Berlin, Germany. They were kept in the animal care facility of 
Institute of molecular biology and tumour research, Marburg. Institutional 
guidelines were followed in handling mice throughout the course of the study. 
4.1.13 Patient samples  
 
Primary CML-progenitor cells were isolated from bone marrow aspirations (30ml) 
during diagnostic biopsies of patients with first diagnosis (FD) of chronic phase of 
CML (table 1) or during routine follow up biopsies for cytogenetic analysis of 
patients during at least MMR (table 2). Patients were treated within multicenter 
CML studies in Mannheim or Marburg University Clinic and gave written 
informed consent to the donation. (Ethics proposal number 35/08 and 09/04, The 
Ethics Committee of University of Marburg) 
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4.1.14 Buffers and solutions 
10%APS (W/V): 1g ammoniumpersulfat in 10ml destilled water. 
10×Electrophoresis buffer 
250mM Tris-OH, 
1.9M Glycine,  
 2.5%SDS. 
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MACS buffer 
2µM EDTA,  
0.5%BSA in PBS. 
 
10× Red blood cell lysis buffer  
 Dissolved the follow 
8.02g Ammoniumchlorid, 
1g potassium bicarbonate,  
0.037g EDTA with H2O to 100ml. 
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Radioimmuno-precipitation Assay Buffer (RIPA Buffer)  
20 mM Tris pH 7.5  
150 mM NaCl  
1% Nonidet P-40  
0.5% Sodium Deoxycholate  
1 mM EDTA  
 0.1% SDS 
 
Protein Loading Buffer (1X SDS gel loading buffer) 
50 mM Tris-Cl (pH 6.8) 
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100 mM Dithiothreitol 
2% SDS 
0.1% Bromophenol blue 
10% Glycerol 
 
Sodium dodecyl sulphate -Polyacrylamide gels (SDS-PAGE) 
Resolving Gel 
Component volumes (ml) per 10 ml gel mix for 8% to 12% 
H2O 3.3 - 4.6 ml 
30% acrylamide mix 2.7 ml - 4.0 ml 
1.5 M Tris (pH 8.8) 2.5 ml 31
10% SDS 0.1 ml  
10% ammonium persulfate 0.1 ml  
TEMED 0.004 ml 
 
Stacking Gel 
Component volumes (ml) per 3 ml gel mix for 10% to 15% 
H2O 2.1 ml 
30% acrylamide mix 0.5 ml 
1.0 M Tris (pH 6.8) 0.38 ml 
10% SDS 0.03 ml 
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32
10% ammonium persulfate 0.03 ml 
TEMED 0.003 ml 
 
Strip-buffer 
0.1M β–Mercaptoethanol,  
2% SDS and 
 62.5mM Tris HCL (pH 6.7). 
 
1×TAE (pH 8.0) buffer  40mM Tris-acetate/1mM EDTA. 
 
10× TBS buffer  200mM Tris-OH pH 7.5, 1.37M NaCl. 
 
1× TBST buffer 1L 1×TBS and 1ml Tween 20. 
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Table 1 CML patient details (MMR patients) 
 
Patient 
(gender, age§) 
 
Euro Risk 
Score 
 
Dose of IM 
 
 
Years from 
First 
Diagnosis 
 
Years on 
IM 
 
Molecular Remission 
at the time of Sorting 
(IS) 
 
Most Recent 
Molecular 
Remission (IS) 
1 (f, 59) low 
831 
400 mg 1 * 
2.3 ‡ 
1 
2.3 
CMR CMR 
2 (f, 39) low 
614 
800-400 mg 2 † ‡ 
3 * 
4 ‡ 
2 
3 
4 
0.033% 
0.0097% 
0.019 % 
0.017% 
 
3 (m, 73) interm 
911 
400 mg 3 † 
4 * ‡ 
3 
4 
CMR CMR 
4 (m, 57) interm  
1313 
400mg +IFN 4* 4 0.019% 0.0076% 
5 (m, 57) interm 
1118.3 
400 mg 2.4 * ‡ 2.4 0.025% 0.011% 
6 (m, 71) interm  
870.5 
800-400 mg 0.10 * 
1.10 ‡ 
0.10 
1.10 
CMR 
CMR 
CMR 
CMR 
7 (m, 31) interm 
1098.1 
400 mg 1 * 1 0.26 % 0.068% 
8 (f, 59) unknown 400 mg 2.1 * 2.1 CMR CMR 
9 (m, 58) interm 
1438 
800 mg 2.7 * 2.7 0.0025% 0.023% 
10 (f, 41) low 
445.3 
400 mg 1.9 † ‡ 
3 * 
4 ‡ 
1.9 
3 
4 
0.014% 
0.064% 
0.031% 
 
0.031% 
 
11 (f,  80)  400 mg 1 * 1   
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12 (m, 53) interm 
1432 
400 mg 1.7 † 
2.7 * ‡ 
3.8 ‡ 
1.7 
2.7 
3.8 
0.24% 
0.041% 
0.034% 
0.034% 
 
13 (m, 38) low  
369.1 
400 mg 6.3 † 5.6 0.047% 0.041% 
14 (m, 56) unknown 400 mg 7.4 † 7.4 CMR CMR 
15 (m, 27) low 
245.2 
400 mg 4.9 † 4.9 CMR CMR 
16 (f, 40) low 
699.5 
800-400 mg 1 † ‡ 
2.10 ‡ 
1 
2.10 
0.012% 
0.0085% 
0.0085% 
 
17 (f, 64) interm  
 994.4 
800-400 mg 2.3 † 2.3 0.025% 0.0097% 
18 (f, 73) interm 
1443.7 
400 mg 4.5 † ‡ 4.3 0.049% 0.019% 
19 (m, 67) low  
749  
800 mg 4.5 4.5 0.012% 0.027% 
* Analysis of  bcr/abl expression in individual colony forming units, ‡ Analysis of bcr/abl expression in total sorted fractions, † 
Analysis of bcr/abl expression by nested PCR 
Abbreviations: cmR, complete molecular remission; IS, international scale; conventional; m, male; f, female;  
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Table 2  CML-patient details (first diagnosis)  
 
Patient 
(gender, age) 
Risk Score Karyotype 
1 (m, 77) interm 
(1035) 
46,XY, 
t(9;22)(q34;q11) 
 
2 (m, 69) interm 
(994.4) 
46,XY, 
t(9;22)(q34;q11) 
 
3 (m, 69) high 
(2580) 
46,XY, 
t(9;22)(q34;q11) 
 
4 (f , 48) low 
(203.9) 
46,XX, 
t(9;22)(q34;q11) 
 
5 (f, 62) interm 
(1379.6) 
46,XX, 
t(9;22)(q34;q11) 
 
6 (m, 35) low 
(471.6) 
46,XY, 
t(9;22)(q34;q11) 
 
7 (f, 51) interm 
(917.2) 
46,XX, 
t(9;22)(q34;q11) 
 
8 (f, 44) low 
(123.9) 
46,XX, 
t(9;22)(q34;q11) 
 
9 (m, 38) low 
(409.4) 
46,XY, 
t(9;22)(q34;q11) 
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Abbreviations:  m, male; f, female                         
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4.2 METHODS 
4.2.1 Isolation of bone marrow mononuclear cells (BMMNCs) 
 
BMMNCs were isolated by means of Ficoll-Hypaque density-gradient 
centrifugation. Briefly, carefully added bone marrow on the top of Ficoll in the 
50ml tube, centrifuged for 20 minutes at 800g, middle layer cells were carefully 
taken out and washed with PBS, lysed with 1× red blood cell lysis buffer for 5 
minutes to remove red blood cells, again washed with PBS. 
4.2.2 Enrichment of CD34 positive cells 
 
BMMNCs resuspended in MACS buffer (0.2M EDTA, 0,25g/ml BSA) were 
mixed with FcR blocking reagent and CD34 magnetic micro beads and incubated 
on ice for 20 minutes. The mixture was loaded on pre-washed column with MACS 
buffer, which was entrapped in strong magnetic field. The column was then 
washed with MACS buffer twice. The cells were harvested by removing the 
column from the magnetic field. CD34+ cells were washed with MACS buffer and 
immediately used for sorting of HSC and myeloid progenitors. 
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4.2.3 Separation of HSC and progenitors from human bone 
marrow 
 
 MACS-enriched CD34+ cells from FD and MMR patients were stained with 
FITC-conjugated antibodies against lineage antigens including CD2 (S5.2), CD3 
(HIT3a), CD4 (RPA-T4), CD8 (HIT8a), CD14 (MΦP9), CD19 (ID-3), CD20 
(2H7), CD56 (NCAM 16.2) and GPA (HIR2) (BD Bioscience, Heidelberg, 
Germany) to gate for lin-negative (lin-) cells. In addition, cells were also stained 
with PE-Cy 7 conjugated anti-CD34 (8G12), PerCP-Cy5.5 conjugated anti-CD38 
(HIT2), PE conjugated anti-CD123 (9F5), APC conjugated anti- CD45-RA 
(HI100) antibodies (BD Bioscience, Heidelberg, Germany) to define a population 
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that enrich for hematopoietic stem cells (HSC) referred to as lin-CD34+CD38-. 
Myeloid progenitor subpopulations were sorted from the lin-CD34+CD38+ fraction 
with antibodies against CD45-RA and IL3-receptor α (IL-3Rα), which separated 
three distinct populations: common myeloid progenitors (CMP) as Lin-
CD34+CD38- IL-3Rαlow CD45RA-, candidate granulocyte macrophage progenitors 
(GMP) as Lin-CD34+CD38- IL-3RαlowCD45RA+) and megakaryocyte erythroid 
progenitors (MEP) as Lin-CD34+CD38- IL-3Rα-, CD45RA-. Cells were analyzed 
and sorted as previously described by MoFlo cytometer (Wang, Y. Blood 2007) 
4.2.4 Retroviral infection and generation of stable cell lines 
 
Retroviral particles were generated by transient calcium phosphate co-transfection 
of phoenix eco cells with the retroviral vector plasmid Mig 210 (kind gift from Dr. 
W. Pear, University of Pennsylvania, Philadelphia, PA), MigR1, pSF91-ICSBP, 
pSF91, pBABE puro-Bcl-2, followed by harvesting of virus containing 
supernatant after 2 days. Transduction was carried out by spinoculation (2500 
rpm) for 90 min at 32°C in presence of polybrene 4ug/ml, followed by 48 hr of 
incubation. Retroviral supernatant were used to transduced the 32D and mice bone 
marrow cells.   
37
Green fluorescent protein positive (GFP+) (BCR/ABL)-high and -low populations 
32D cells (32D/BA-high and -low), 32D-vector, 32D-ICSBP, 32D-BA, 32D BA-
ICSBP, 32D- BA-AID-GFP and 32D-BA-ICSBP-AID-GFP cells were selected by 
flow cytometry sorting.   
To generate 32D BA-Bcl-2 and 32D BA-ICSBP-Bcl-2, 24 h after infection with 
pBABE puro-Bcl-2 retrovirus, cells were placed in fresh growth medium and 
selection with 2µg of puromycin/ml was initiated. After about 15 days, individual 
clones picked from 96 well plates and transferred to 24 well plate and expanded to 
generate cell clones stably expressing Bcl-2.  
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4.2.5 Retrovirus transduction of primary cells 
 
Femur and tibia were collected from 6 to 8 week old C57Bl/6 mice and bone 
marrow was harvested by flushing with syringe and 26-gauge needle. Bone 
marrow cells were prestimulated for 48 hr in serum free X-Vivo medium 
(Biowittakar, Lonza) supplemented with 10% BSA, 1%(vol/vol) penicillin/ 
streptomycin, 200 µM l-glutamine, 6 ng/ml recombinant murine IL-3 (Immuno 
tools), 10 ng/ml recombinant murine IL-6 (Immuno tools), and 50 ng/ml 
recombinant murine stem cell factor (SCF; Immuno tools). Subsequently, cells 
were resuspended in virus containing supernatant and plated on retronectin -coated 
plates pre-exposed to viral supernatants for 30 min to allow binding of virus 
particles and thereby increase the cell exposure to virus. Cells were harvested 48 
hours after the virus exposure and GFP+ cells were sorted using a MoFlo in two 
separate populations referred as GFP+ (BCR/ABL)-high and –low cells.  
4.2.6 Cell culture 38
 
32Dcl3, K562 and U937 was obtained from DSMZ cell culture collection (DSMZ, 
Braunschweig, Germany) and maintained in RPMI medium supplemented with 
10% FCS and 1% penicillin/streptomycin. 32Dcl3 were additionally 
supplemented with IL-3 (supplied as 10% WEHI-conditioned media), GFP+ 32D-
BA high and 32D-BA low cells were generated after retrovirus transduction were 
maintained as 32D cells, but without supplementation of IL-3. BCR-ABL 
expressing GFP+ primary cells from mice bone marrow were cultured in IMDM 
medium supplemented with 20% FCS, (vol/vol), 1% penicillin/ streptomycin, 6 
ng/ml recombinant murine IL-3, 10 ng/ml recombinant murine IL-6, and 50 ng/ml 
recombinant murine stem cell factor (SCF) (Immuno tools, Friesoythe, Germany). 
M210B4, Phoneix Eco and PlateE cells were cultured in DMEM medium 
supplemented with 10% FCS, 1% penicillin/streptomycin.  
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4.2.7 Separation of HSC and myeloid progenitor from mice bone 
marrow 
 
To isolate the Lin- cells, bone marrow cells were stained with biotinylated lineage 
cocktail (militeney biotech) and incubated on ice for 20 min. Anti-biotinylated 
antibody was added and further incubated for 20 min. Lin- fraction were isolated 
using MACS columns. Lin- bone marrow was transduced with Mig 210 virus and 
after 48 hours cells were stained with PE-conjugated anti CD34, APC-conjugated 
anti c-Kit, pecific blue-conjugated anti Sca1,  PE-Cy7-conjugated anti FcγR 
antibodies.  
After staining, cells were analyzed and sorted by MoFlo cytometer (Dako 
Cytomation, Fort Collins, CO). HSC identified as lin-c-Kit+Sca1+ (LSK cells) and 
myeloid progenitor were sorted from lin-c-Kit+Sca1- (LK cells) with antibody 
against FcγR and CD34 which clearly separated in three distinct populations in 
untransduced bone marrow. Common myeloid progenitor (CMP) were identified 
as lin-c-Kit+Sca1- FcγRlow CD34+, candidate granulocyte macrophase progenitor 
(GMP) were identified as lin-c-Kit+Sca1- FcγRhigh CD34+  and MEP were 
identified as lin-c-Kit+Sca1- FcγRlow CD34- .  
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4.2.8 Preparation of whole protein extract from Cells 
 
Cells were harvested and washed with ice cold PBS and then resuspended in 
whole cell extract buffer. Then transferred them into 1.5 ml tubes and incubated 
on ice for 30 min. The cell suspension was centrifuged at 13,000 rpm for 10 min 
at 4°C and supernatant was saved as whole cell extract in another 1.5 ml tube, 
which was stored for future use at -80°C. Protein concentration was determined by 
BSA kit according to manufacturer’s protocol.  
4.2.9 Polyacrylamide gel electrophoresis of proteins  
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The polyacrylamide gel electrophoresis (PAGE) of proteins was performed in 
presence of 0.1% SDS according to standard Laemmli method. Protein samples 
were prepared by mixing with 1X SDS-PAGE sample loading buffer and boiling 
for 5 min to denature the protein. After Polymerization of gel, protein samples 
were loaded in the wells (one well was loaded with protein marker). 
Electrophoresis was performed at constant voltage of 120 V until the dye reached 
the bottom of the gel. Following the run, gels were electro-blotted onto the 
nitrocellulose membrane (Amersham Biosciences).  
4.2.10 Western blotting 
 
For western blotting of proteins from gel onto nitrocellulose membrane semidried 
blot apparatus (BIO-RAD) was used according to instructions provided by the 
manufacturer. Electro-blotting was performed at a constant current of 200 milli-
amperes for 1 hr. Following which the membrane was incubated in 5% nonfat 
milk in TBST for blocking with gentle shaking at room temperature for 2 hrs. 
After that, the blocking solution was discarded and after washing twice with 1X 
TBST the membrane was incubated with an appropriate dilution of primary 
antibody for another 2 hrs with gentle shaking. Thereafter, the blot was washed 
thrice with 1X TBST for 5 min each. After washing, the blot was incubated with 
horseradish peroxidase conjugated secondary antibody solution for 2 hrs. The blot 
was washed as described above and protein were visualized and developed with 
ECL developing solution according to the manufacturer’s instruction. 
40
4.2.11 Long-term culture-initiating cells (LTC-IC assay) 
 
Irradiated M210B4 fibroblasts cells were established as feeder layer, 24 hr before 
adding the sorted cells, in collagen coated 24-well plate. 10,000 sorted HSC, 
CMP, GMP and MEP cells from CML patients were cultured on the irradiated 
feeder layer in MyeloCult medium (StemCell Technologies H5100) with 
hydrocortisone according to the manufacturer’s instructions. Cultures were 
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maintained for 5 weeks with weekly half medium exchanges. One half of the 
medium and cells removed and replaced with fresh medium for five weeks. After 
5 weeks of culture, floating and adherent cells were harvested using Trypsin-
EDTA and washed with Myelocult medium. Cells were plated into methyl 
cellulose medium (StemCell Technologies H4435) and colonies derived from 
long-term culture-initiating cells (LTC-ICs) were counted after two weeks.  
4.2.12 Colony forming cell (CFC) assays 
 
Colony forming unit assays were performed by plating 500 sorted HSC, CMP, 
GMP, and MEP into a 35 mm culture dish (Cellstar, Frickenhausen, Germany) 
using 1ml complete methylcellulose agar (MethoCult® medium H4435, StemCell 
Technologies) containing all necessary cytokines and reagents for CFU growth. 
After 14-18 days individual CFU were picked for RNA isolation. For assessment 
of CFU growth of BCR-ABL or mock-transduced murine progenitors 1000 GFP-
positive cells were seeded in triplicate Methocult® agar in presence of IM at 3µM 
concentration or solvent (as control). Emerging colonies were counted after 14 
days.   
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4.2.13 RNA isolation 
 
RNA was isolated from 4000 sorted bone marrow cells that had been pre-enriched 
before sorting for CD34+ cells using the MACS methodology. Cells were directly 
sorted (Figure 1A) into RLT-lysis buffer of the RNeasy micro kit (Qiagen, Hilden, 
Germany). Alternatively one individual CFU, containing approximately 100-200 
cells was picked from the CFU agar and transferred into RLT buffer. Total RNA 
from primary cells and cell lines was extracted using Qiagen RNeasy mini kit. 1-5 
X 106 cells were lysed in RLT buffer containing β-mercaptoethanol and passed 
through QIA shredder spin columns. Ethanol was added to adjust binding 
conditions and sample was applied to the QIAamp spin columns. RNA was bound 
to the silica-gel membrane during a brief centrifugation step. Contaminants were 
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washed away and total RNA was eluted in RNase-free water and stored at -80°C. 
RNA was reverse transcribed into cDNA in a total volume 20 µl using Superscript 
reverse transcriptase (RT) (Qiagen, Hilden, Germany) and Random Hexamer 
primer (Fermentas, St. Loen-Rot, Germany) under standard condition and stored 
at -20°C until analyzed.  
4.2.14 Nested PCR for bcr-abl mRNA 
 
For qualitative assessment of bcr/abl expression, cDNA from 4000 cells were used 
for the first round of PCR amplification at an annealing temperature of 60°C. 
After 40 cycles of amplification 4µl of first stage product was subjected to an 
additional 40 round of PCR amplification using internal nested primers. 
Amplification of the β-actin housekeeping gene (annealing temperature 55°C) was 
performed to ensure comparable loading and cDNA quality. 
4.2.15 Quantitative bcr-abl PCR  42
 
Quantitative PCR analysis for bcr-abl expression of bone marrow samples was 
performed using the IPSOGEN® kit and protocol (Luminy Biotech Enterprises, 
France), which quantifies bcr-abl copy numbers relative to abl copy number using 
a real-time TaqMan® method and an ABI Prism 7700 sequence detector (Perkin 
Elmer Applied Biosystems, Darmstadt, Germany). 5µl cDNA were used as 
template in a 25µl PCR reaction. Cycling conditions were as recommended by the 
manufacturer initial denaturation at 50°C 2 min, 95°C for 10min, 50 cycles of 
amplification at 95°C for 15 sec, annealing at 60°C for 1 min. Raw ct value 
obtained from sample analysis was transformed in to an absolute copy number by 
plasmid dilution standard curve. Ratio of bcr-abl copy number to abl copy number 
is expressed as the normalized copy number (NCN=bcr-ablCN/ ablCN). 
4.2.16 N-ethyl-N-nitrosourea (ENU) mutagenesis 
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ENU was dissolved in dimethlsulfoxid (DMSO) at 50 mg/ml and stored in 
aliquots at –80°C. ENU was added to 32D/BA-high and 32D/BA-low cells (5 × 
106 cells/ml) at a concentration of 50 µg/ml followed by culturing for 24 hours. 
After washing three times with medium, cells were allowed to expand over one 
week. 32D/BA-low and –high cells were transferred into 96-well plates at 1 × 105 
cells/well in a culture volume of 200 µl and supplemented with 2µM IM. Cultures 
were maintained for 4 weeks, replacing half of the medium every 48 hours and IM 
to yield a final concentration of 2µM. Wells were observed for cell growth by 
visual inspection under an inverted microscope and media color change every 2 to 
3 days for at least 4 weeks. 
 
4.2.17 Apoptosis measurement 
 
Apoptosis was measured using the Annexin V-FITC apoptosis detection kit 
according to manufacturer’s recommendations. Briefly, 1.5×105 cells were 
collected and washed once with PBS, then incubated with 5µl FITC conjugated 
annexin V antibody in 195µl 1× binding buffer at room temperature for 10 
minutes in dark. Unbinding annexinV antibody was removed by washing with 
1×binding buffer. The cells were resuspened in 1× binding buffer and acquired by 
FCAScan immediatedly after stained with 20ug/ml propidium iodide (PI). PI and 
annexinV double negative cells were recognized as surviving, Annexin V positive 
and PI negative cells as early apoptosis, PI positive cells was counted as late 
apoptosis. 
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4.2.18 Cell cycle analysis 
 
1 x 106 cells were harvested and washed once with PBS then resuspended in 500µl 
PBS. Cells were fixed by dropping 3 ml 70% cold ethanol (stored at -20°C) while 
vortexing and stored at 4°C for overnight. Before measurement, samples were 
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washed once with PBS and incubated in 1 ml PBS containing 50µg PI and 200µg 
RNase for 30 minutes at room temperature. Following incubation, cell cycle was 
analyzed by FACS. 
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5 RESULTS 
5.1 Low BCR-ABL expression levels in hematopoietic precursor 
cells enable persistence of chronic myeloid leukemia under IM 
5.1.1 CML persistence in primitive and proliferating precursor 
compartments during MMR  
IM induces high rates of stable complete cytogenetic remissions (CCR) in chronic 
phase of CML (Druker, B.J, N Engl J Med 2006) (Hochhaus, A, Leukemia 2009). 
However, despite long-term IM therapy, BCR/ABL-mRNA and BCR/ABL-positive 
CFU remain detectable during CCR (Hughes, T.P N Engl J Med 2003, Bhatia, R, 
Blood 2003). Stem cell quiescence and BCR-ABL over expression may contribute 
to IM insensitivity of CML-HSC (Guastafierro, S, Leuk Res2009).  
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Figure 7: Sorting strategy of MACS-enriched CD34+ cells. The lineage negative sub-
fraction was divided into lin-CD34+CD38- cells, enriching for HSC and a lin-CD34+CD38+ fraction, 
which was further gated according to the IL-3Rα and CD45RA staining into CMP, GMP, and MEP 
as indicated. 
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4000 cells of each population were analyzed for the presence of bcr-abl using a 
qualitative nested reverse transcriptase-PCR (RT-PCR) approach. As a first step to 
obtain insight into the nature of disease persistence in MMR patient, bone marrow 
of ten MMR patients was sorted into HSC, CMP, GMP, and MEP (Figure 7).  
BCR-ABL was detected in the HSC enriching population of seven of ten (7/10) 
MMR patients, but also in the CMP (6/10), GMP (10/10), and MEP (8/10) fractions 
of the same MMR patients (Figure 8A), indicating CML persistence of primitive 
and mature precursors under IM. 
Persistence of mature progenitor was in contrary to the current view that IM 
preferentially kills dividing precursors. Therefore, we next asked, whether 
expansion of BCR-ABL positive progenitor compartment in presence of IM is due 
to acquisition of self renewal capacity. To determine this primitive and committed 
progenitor sorted from HSC, CMP, GMP and MEP compartment were subjected to 
Long term culture initiating cells assay (LTC-IC), followed by committed 
progenitor assay (CFU) (Eaves et al., 1992; Sutherland et al., 1990; Udomsakdi et 
al., 1992). After 5 weeks of LTC-IC, cells were suspended in methylcellulose 
medium and plated for CFU assay for detection of clonogenic cells per well. Clones 
that emerged after CFU assay were picked and BCR-ABL expression was analyzed 
by nested PCR. Similarly, CFU emerged from bone marrow of healthy donor and 
FD patients were analyzed for BCR-ABL expression by nested PCR. Interestingly, 
CFU obtained from first diagnosis patient showed a faint band after first round of 
PCR, whereas no BCR-ABL specific amplification was seen in MMR patient’s 
CFU (Figure 8B). This observation led to the intriguing possibility that low BCR-
ABL expressers survive IM therapy. As expected, nested PCR of CFU obtained 
from healthy donor was not positive for BCR-ABL transcript (Figue 8B). This 
assay resulted in the similar trend of CML-CFU and healthy donor CFU formation. 
So it cannot be used to detect self renewal capability of CML-CFU of MMR 
patients.  
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Figure 8: Detection of BCR-ABL mRNA transcripts in bone marrow 
subpopulations of CML-FD and MMR patient. (A) A total of 4000 cells from marrow 
subsets as indicated of MMR patients were analyzed for BCR-ABL expression using a qualitative 
nested PCR analysis; corresponding β-actin expression is shown as reference gene to demonstrate 
cDNA integrety. (B) 10,000 cells from each subfraction were cultured on irradiated feeder layer. 
After 5 weeks cells from each sub-fraction were seeded in 1 ml of methylcellulose medium with 
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cytokine. CFU formation in MMR patients (left). BCR-ABL expression level was determined by 
nested PCR in individual CFU from healthy donor, FD and MMR patient (right). (C) Quantitative 
real time BCR-ABL PCR normalized to ABL. Columns represent mean expression of BCR-ABL ± 
s.e.m. in sorted subfraction (as indicated) from CML patiens at diagnosis (CML-FD) or during 
MMR; *** indicates a p-value of < 0.001 according to 2way ANOVA analysis with Bonferroni 
adjustment for multiple comparisons. 
Next a quantitative BCR-ABL PCR was performed using cDNA of primitive and 
committed bone marrow sub fractions of patients at CML-FD and during MMR. 
This revealed that BCR-ABL transcript level declined during MMR, both, in the 
progenitor and HSC compartments (Figure 8C). Thus, IM apparently eliminated 
BCR-ABL-positive cells from the mature and primitive bone marrow fractions.    
5.1.2 Clearance of bone marrow from BCR-ABL positive 
precursors during MMR 
Next we investigated in more detail, whether lower BCR-ABL expression during 
MMR was due to decline in the number of persisting CML precursors. In total, 251 
single CFU from six FD patients and 247 CFU from 12 MMR patients, sorted from 
HSC, CMP, GMP, MEP compartments were analyzed by quantitative RT-PCR for 
bcr-abl mRNA expression. Only informative CFU yielding sufficient mRNA were 
considered. Out of 184 informative CFU obtained from CML FD patients, 173 were 
BCR-ABL-positive (94%). In contrast, only 74 of 165 CFU (44%) derived from 
twelve MMR patients were BCR-ABL positive (Figure 9A). The percentage of bcr-
abl-positive CFU during MMR was quite varied (0%-85%, mean: 44%) (Figure 
9B), but there was consistently less BCR-ABL positive CFU during MMR 
irrespective of whether they were isolated from committed (CMP, GMP and MEP) 
or primitive, HSC containing fraction (Figure 9C). This suggested that IM 
eliminates CML from all marrow compartments. 
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Figure 9: Frequency of BCL-ABL-negative and BCR-ABL-positive CFU at 
diagnosis and during MMR. BCR-ABL specific real time PCR from individual CFU: to 
identify the frequency of BCR-ABL-positive versus normal, that is, BCR-ABL-negative CFU at the 
time of CML-FD and MMR. (A) The sum of BCR-ABL-positive and normal CFU is illustrated by 
dark versus grey bars, respectively. (B) The amount of BCR-ABL positive and normal CFU is 
shown for each patient individually. (C) The number of BCR-ABL-positive and normal CFU is 
depicted depending on the bone marrow compartment of origin. 
Moreover, it was implied that the lower BCR-ABL expression level found in the 
sorted sub-fractions during MMR (Figure 9C) resulted, at least in part, from a 
decreased number of BCR-ABL-positive CFU. 
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5.1.3 Reduced BCR-ABL expression in persisting CML precursors  
Lower BCR-ABL expression during MMR (Figure 8B) could also be the 
consequence of a selective persistence of precursors with lower BCR-ABL 
expression.  
 
 
Figure 10: BCR-ABL expression analysis in individual CFU. The BCR-ABL 
expression levels of BCR-ABL-positive CFU from CML-FD and during MMR are shown. (A) Each 
column represents the BCR-ABL expression value of an individual CFU harvested from the 
indicated subfraction. (B) BCR-ABL expression of all analyzed BCR-ABL-positive CFU from 
CML-FD (grey) versus MMR (dark). Bars represent means ± s.e.m.; *** indicates high statistical 
significance (p<0.0001) according to Mann Whitney t-test. (C) Comparison of the BCR-ABL 
expression level of BCR-ABL-positive CFU from CML-FD (grey) versus MMR (dark) sorted from 
bone marrow compartments as indicated. Bars represent mean values ± s.e.m; *** indicates p-value 
<0.0001, ** p<0.01, and * p<0.05. Statistical significance was assessed using a 2way ANOVA 
analysis with Bonferroni adjustment for multiple comparisons. 
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When looking at the BCR-ABL expression level of individual CFU, we first 
noticed a substantial variability in BCR-ABL expression repertoire of clones from 
CML-FD expressed on average significantly more BCR-ABL mRNA than BCR-
ABL-positive CFU from MMR patients (Figure 10B). This was true irrespective of 
whether comparing CML-FD and MMR CFU from the primitive HSC containing 
compartment, or the various committed progenitor compartments (Figure 10C). 
5.1.4 Low BCR-ABL expression confers IM insensitivity of primary 
progenitors 
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Figure 11: Effect of BCR-ABL expression level in primary bone marrow cells 
on IM sensitivity. 
(A) BCR-ABL-GFP vector transduced murine BMMNC were analyzed by FACS for GFP staining 
intensity and sorted into GFP-high (BM/BA-high) and -low (BM/BA-low) fractions using gates as 
indicated (left); transduced cells were cultured for 72 hours after sorting and total protein was 
extracted. Western blotting was performed using anti-Abl antibodies. The membrane was reprobed 
using an anti-Actin antibody as a loading control. (right) (B) IM-induced apoptosis in BM/BA-high 
and BM/BA-low cells as assessed by propidium iodide staining. Cells were cultured for 48h with 3 
µM IM and cell death was measured by PI positivity using flow cytometry. Left; representative 
FACS profile, gated cells are PI-positive apoptotic cells. Right; summary of results obtained from 
three independent experiments. Columns and error bars represent mean ± s.e.m.; * indicates p<0.05. 
51 
 
Results 
Based on the findings above, it was tempting to speculate that IM therapy 
preferably killed clones with higher BCR-ABL expression, resulting in the 
persistence of IM-insensitive disease with lower BCR-ABL expression. In order to 
experimentally assess, whether low BCR-ABL expression confers IM insensitivity, 
primary mouse bone marrow cells were transduced with a BCR-ABL construct also 
encoding for the expression of green fluorescence protein (GFP). 
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Figure 12: Effect of BCR-ABL expression level in primary bone marrow CFU. 
1000 BM/BA-high and -low cells were sorted and seeded in 1ml of semisolid methylcellulose 
medium with and without 3µM IM, after 14 days colonies were counted. The data shown were 
obtained from 3 independent experiments, columns represent mean ± s.e.m., *** indicates p<0.001 
according to Mann Whitney t-test. 
The GFP-positive fraction was sorted into a GFP-high and a GFP-low expressing 
population to select for low and high levels of BCR/ABL (Figure 11A). The GFP 
staining intensity correlated with the BCR-ABL protein levels as confirmed by 
western blotting (Figure 11A). Sorted BCR-ABL-overexpressing bone marrow cells 
(BM/BA-high) and BCR-ABL-low expressing bone marrow cells (BM/BA-low) 
were treated with IM at a concentration of 3µM for 48h in presence of serum and 
growth factors. Intriguingly, BM/BA-low underwent significantly less apoptosis 
than BM/BA-high (Figure 11B). Moreover, IM treatment inhibited colony 
formation significantly more potently in BM/BA-low than in BM/BA-high 
(p=0.006). This provided evidence that lower BCR-ABL expression reduces IM 
sensitivity in primary bone marrow progenitors (Figure 12). There was no 
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significant difference in the number of colonies in BM/BA-high and BM/BA-low in 
the absence of IM (Figure 12). 
5.1.5 BCR-ABL expression level regulate kinase mutation 
development 
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Figure 13: Effect of BCR-ABL expression and chemical mutagenesis by ENU 
on kinase point mutation rates. (A.) BCR/ABL-transduced 32D cells were sorted by flow 
cytometry on the basis of GFP staining intensity as 32D/BA-low and 32D/BA-high cells (left panel). 
BCR-ABL protein expression was confirmed 72 hours after sorting by western blotting using anti-
Abl antibody. The blot was reprobed with anti-Actin antibody as a loading control (right panel). (B) 
Cell-based BCR-ABL kinase mutation assay. 32D/BA-high and 32D/BA-low cells were exposed to 
ENU and one week later exposed for 4 weeks to 2µM of IM. The number of outgrowing resistant 
clones is given relative to the total input cell number per 96 well plate. Data are representing mean± 
s.e.m. of 3 independent experiments; *** indicates p<0.001, * indicates p<0.05 according to 2way 
ANOVA analysis with Bonferroni adjustment for multiple comparisons. 
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BCR-ABL kinase mutations cause IM resistance (Gorre, M.E., Science, 2001; 
Shah, N.P.Cancer cell, 2002) and supposedly mediate persistence under IM (Chu et 
al., 2005). We asked, to which extend BCR-ABL expression may impact BCR-
ABL kinase mutation generation. A cell-based BCR-ABL -kinase mutagenesis 
screen was employed, which produces BCR-ABL -kinase point mutations as the 
main resistance mechanism (Bradeen, H.A, Blood, 2006).  
The murine myeloid 32D cell line was transduced with a BCR-ABL plasmid 
encoding also for GFP. Resulting 32D-BA cells were sorted according to their GFP 
staining intensity into putative BCR-ABL-high (32D/BA-high) and low (32D/BA-
low) expressing cell populations (Figure 13A). Western blotting again confirmed 
that BCR-ABL expression level correlated with the GFP staining intensity (Figure 
13A). 32D/BA-low and 32D/BA-high cells were exposed, respectively, to IM at 
2µM and wells showing outgrowth of viable cells after 21-28 days were counted as 
IM resistant clones. 
32D/BA-high cells generated significantly more resistant clones compared to 
32D/BA-low cells. Intriguingly, the impact of chemical mutagenesis by ENU on the 
frequency of IM resistance development was significantly weaker than the effect of  
high BCR-ABL expression, because the number of emerging IM-resistant clones 
was a multiple fold lower in ENU-treated 32D/BA-low cells than in ENU-naïve 
32D/BA-high cells (p=0.006) (Figure 13B). Hence, persistence of precursors with 
low Figure 13B expression would explain the low propensity of kinase mutation 
development which is clinically observed during MMR. 
5.1.6 BCR-ABL expression level of CML-CFU after in-vitro 
treatment with IM 
We also analyzed whether an in-vitro IM exposure of primary CML precursor also 
resulted in a selective survival of low expressing BCR-ABL CFUs. Sorted cells 
from FD patients were seeded in soft agar in the presence and absence of IM and 
resulting CFU were analyzed for BCR-ABL expression levels.  
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Figure 14: BCR-ABL expression level of CML-CFU after in-vitro treatment 
with IM. A total of 500 cells from each of the indicated marrow subsets were sorted and seeded in 
1ml of semisolid methylcellulose medium with and without 3µM IM. After 14 days colonies were 
counted. (A) Number of CFU obtained from untreated and IM treated CFU culture. The data shown 
were obtained from 4 FD patients, columns represent mean ± SEM, * indicates p<0.01. (B) 
Expression of BCR-ABL was determined by quantitative PCR in untreated (dark bar) and IM treated 
(gray bar) single CFU. The data shown were obtained from 4 FD patients, columns represent mean ± 
SEM, * indicates p=0.056 
Out of 172 informative CFU analyzed from mock treated control, 166 were BCR-
ABL positive (95%). In contrast, 15 of 34 CFU (44%) derived from IM treated CFU 
were BCR-ABL positive. Although, the number of colonies was significantly 
reduced in IM-treated primitive and committed progenitor compared to untreated 
control (figure 14A). Surviving CFU after IM treatment expressed on average lower 
amounts of BCR-ABL than those before IM exposure. Thus, in-vitro treatment 
recapitulated the in vivo finding of a preferential survival of low BCR-ABL 
expressing progenitor cells. (figure 14B).  
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5.2 ICSBP deficiency in CML confers IM resistance but restricts 
BCR-ABL kinase point mutation development 
5.2.1 ICSBP expression in BCR-ABL induced bone marrow 
Expression of the ICSBP protein was found to be downregulated in BCR-ABL 
induced murine CML-like myeloproliferative disease and forced co-expression of 
ICSBP inhibits BCR-ABL induced CML-like myeloproliferative disease (Deng and 
Daley, 2001). These findings provide evidence that ICSBP can act as a tumor 
suppressor for BCR-ABL induced CML-like disease. It has been suggested ICSBP 
expression is reduced via increased promoter methylation (Ortmann et al., 2005; 
Tshuikina et al., 2008a; Tshuikina et al., 2008b).  
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Figure 19: Sorting of stem cells and myeloid progenitor cells in mouse bone 
marrow: (A) Lineage negative (lin-) cells were further stained with HSC and progenitor specific 
marker and sorted with MoFlo as lin-c-Kit+Sca1+ (LKS cells) and lin-c-Kit+Sca1- (LK cells). LK 
cells were further sorted into CMP, GMP and MEP. (B) Lin- bone marrow cells were transduced 
with GFP expressing Mig p210 followed by multicolor flow cytometry to sort GFP (BCR-ABL) 
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positive LSK and LK subsets. Viable cells were first gated for GFP+ cells to sort the BCR-ABL 
positive LSK and progenitors (LK) cells. 
To determine whether BCR-ABL directly suppresses ICSBP expression, lin- cells 
from bone marrow of wild type mice were transduced with GFP expressing Mig 
p210 retroviral construct and sorted according to scheme illustrated in figure 19 
(Akashi et al., 2000). Untransduced bone marrow clearly separated into LSK (HSC) 
and LK- fraction. The LK-fraction was further separated into CMP GMP and MEP. 
It was noted that BCR-ABL-transduced bone marrow produces more granulocytes–
monocyte progenitors in bone marrow when compared to control untransduced 
bone marrow. 
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Figure 21: Expression of ICSBP in BCR-ABL transduced cells. LSK and LK cells 
were sorted from Mig210 trasduced and untransduced bone marrow of wild type mice and cultured 
for 17 days in presence of cytokines (SCF, IL-3 and IL-6). Expression of ICSBP was determined by 
real time PCR at indicated time point. Column represents mean ± SEM; *p<0.05 and **p<0.005 
To examine if also the expression of ICSBP is changed in BCR-ABL transduced 
bone marrow sub-populations, expression of endogenous ICSBP in sorted LSK and 
LK cells was examined by quantitative reverse transcriptase-PCR. Sorted GFP 
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(BCR-ABL) positive LSK and LK cells were further expanded in presence of 
cytokines for 2.5 weeks and harvested on indicated time point and ICSBP 
expression was analyzed. Expression level of ICSBP was progressively reduced 
over time compared to the untransduced compartment (figure 21). Among the BCR-
ABL transduced progenitors, expression levels of ICSBP were more down-
regulated in the LK fraction than in the LSK population. Thus, in-vitro BCR-ABL 
transduction of primary bone marrow resulted in decreased levels of ICSBP 
expression. Whether this was a direct or indirect effect remained however unclear.  
5.2.2 ICSBP deficiency confers IM resistance 
Tyrosine kinase inhibitor IM is known to induce cell death in BCR-ABL positive 
cells. We next asked whether BCR-ABL dependent or independent suppression of 
the ICSBP also affects IM response.  
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Figure 23: ICSBP deficiency confers IM resistance (Left) 32D-BA and 32D-BA-
ICSBP cells were cultured for 48 hours with 1µM IM and cell death was measured using PI staining 
and analyzed by flow cytometry. The results shown were obtained from 3 independent experiments, 
column represents mean ± SEM; *p=0.001 and **p=0.0001. (Right) BCR-ABL and ICSBP protein 
expression in transduced cells were accessed by western blot. Cells were cultured for 72 hours after 
sorting and protein was extracted as described in materials and methods. Proteins were detected 
using anti-ABL and anti –ICSBP antibodies. Blots were reprobed with anti-actin antibody as a 
loading control. 
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In order to determine the role of ICSBP in IM induced cell death, 32D cells were 
stably transduced with either Mig p210 plasmid expressing BCR-ABL alone or 
together with another plasmid containing ICSBP to generate 32D-BA and 32D-BA-
ICSBP cell lines respectively. Expression of BCR-ABL and ICSBP was checked by 
western blot (figure 23). IL-3 independent BCR-ABL transformed 32D-BA and 
32D-BA-ICSBP cells were treated with 1µM IM. Induction of cell death occurred 
in time dependent manner and was measured at 24 hr and 48 hr following treatment 
using PI staining. 32D-BA-ICSBP cells were more sensitive to IM induced cell 
death than 32D-BA cells (Figure 23). The difference in the cell death was more 
pronounced at 48 hr compared to 24 hr. 
5.2.3 Over-expression of Bcl-2 protects 32D-BA-ICSBP cells from 
IM induced cell death 
ICSBP regulates IM induced apoptosis in BCR-ABL transformed 32D cells 
(Burchert et al 2004).  It down-regulates one of the key anti-apoptotic gene Bcl-2, 
which is essentially required for BCR-ABL induced transformation, apoptosis, and 
drug resistance (Burchert et al 2004). Therefore, increased apoptosis in 32D-BA-
ICSBP cells might be associated with reduced Bcl-2 levels. We next investigated 
whether enhanced expression of Bcl-2 protects against IM-induced cell death in this 
cell system. In order to analyze the effect of Bcl-2, 32D-BA-ICSBP cells were 
stably transfected with retroviral plasmid containing Bcl-2. Three puromycin-
resistant clones were screened by western blot analysis for expression of Bcl-2, 
BCR-ABL and ICSBP (figure 24).Bcl-2-overexpressing clone (clone 3) was 
selected, expanded in presence of puromycin and examined for IM induced 
apoptosis. 32D-BA, 32D-BA-ICSBP and 32D-BA-ICSBP-Bcl2 cells were treated 
with 0.5, 1 and 2 µM IM for 48 hours, a concentration and time dependent effect 
was observed in all cells. 
59 
 
Results 
                                      
BCR-ABL
Actin
ICSBP
BCL-2
Clone      1        2        3
 
 
Figure 24: Selection of Bcl-2 over expressing clones. 32D BA-ICSBP cells were stably 
transduced with pBABE-puro-Bcl-2 plasmid and selected in presence of 2 µg/ml puomycin for 2 
weeks. Several stable clones were expanded in 24 well plate and expression of BCL-2, BCR-ABL 
and ICSBP protein in three different clones was analyzed by western blot analysis. Blot was again 
reprobed with anti-Actin antibody as loading control.   
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Figure 25: Effect of over-expression of Bcl2 on 32D-BA-ICSBP cells on 
apoptosis.  After culture for 24 hours (left) and 48 hours (right) in presence of IM (0.5-2µM) cells 
were stained with PI and percent cell death was determined by FACS analysis. The results shown 
here were obtained from 3 independent experiments in which each experimental point was the mean 
of triplicate determination.  Significance level are *P<0.0005 and **P<0.005, 32D-BA versus 32D-
BA-ICSBP. 
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As shown in Figure 24, Bcl-2 over-expressing cells were clearly more resistant to 
undergo apoptosis than 32D-BA-ICSBP cells (significance level at 1µM and 2µM 
IM concentration was P<0.005 and P<0.0005 at 24hr and 48 hr respectively, in 
32D-BA-ICSBP versus 32D-BA-ICSBP-Bcl2). Interestingly, in this cell system a 
complete reversal of the ICSBP induced cell death was observed through 
expression of Bcl-2 at 48 hr. However, 32D-BA-ICSBP-Bcl2 cells retained IM –
sensitivity to some extend (approximately 50% apoptosis after 48 hrs). In contrast 
when only Bcl-2 was expressed in 32D-BA cells, these cells were completely IM 
resistant to IM at 2 µM after 48 hours (figure 25). This suggests that ICSBP induces 
IM sensitivity through suppression of Bcl-2. 
Western blot analysis of 32D-BA, 32D-BA-ICSBP and 32D-BA-ICSBP-Bcl2 cells 
treated with IM resulted in similar inhibition of BCR-ABL kinase activity as shown 
from the inhibition of downstream target gene. Interestingly, a significantly higher 
inhibition of phospho-AKT was observed in 32D-BA-ICSBP and 32D-BA-ICSBP-
Bcl2 cells compared to 32D-BA cells after 8 hrs treatment with IM while 
phosphorylation of the BCR-ABL target STAT-5 was completely inhibited by IM 
even at 4 hrs (Figure 26). These results indicate that IM treatment effectively 
inhibited BCR-ABL kinase activity, but that regulation of AKT-signaling may be 
BCR-ABL independent but affected by ICSBP. The AKT substrate FoxO3a, a 
transcription factor known to mediate growth inhibition as well as apoptosis after 
inhibition of AKT pathway, was also regulated by ICSBP. The basal levels of 
FoxO3a protein were higher in 32D-BA-ICSBP and 32D-BA-ICSBP-Bcl-2 cells 
compared to 32D-BA cells. This would be consistent with previous observations 
(Kharas et al., 2004) that increased expression of FoxO3a stimulates apoptosis. 
However, the exact role of ICSBP regulated FoxO3a levels needs to be further 
explored.  
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Figure 26:  BCR-ABL downstream target inhibition by IM. Cells were treated with 
1 µM IM for 8 hours followed by preparation of total cell extract for western blot. Cells A, B and C 
indicate 32D-BA, 32D-BA-ICSBP and 32D-BA-ICSBP-Bcl-2 respectively. Expression of phospho- 
AKT, AKT, phospho-CRKL, CRKL, phospho-STAT-5, BCL-2, ICSBP, BCR-ABL was analyzed at 
indicated time point. Blot was again re-probed with anti-Actin antibody as loading control. 
5.2.4 ICSBP deficiency restricts BCR-ABL kinase point mutation 
development 
BCR-ABL tyrosine kinase mutation represents a common and the best understood 
mechanism of IM resistance in BCR-ABL positive leukemia treated with IM. We 
here ask whether an increased apoptosis response in the presence of ICSBP may 
regulate kinase mutation development. The rate of IM-induced BCR-ABL kinase 
mutations was quantitated in presence and absence of ICSBP using an established 
TKI mutagenesis screen (von Bubnoff et al., 2006; von Bubnoff et al., 2005). This 
screen produces resistant clones almost exclusively via mutation induction in the 
BCR-ABL kinase domain. 
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Figure 28: Role of ICSBP expression and chemical mutagenesis by ENU on 
kinase point mutation rates. Cell-based BCR-ABL kinase mutation assay. 32D-BA and 32D-
BA-ICSBP cells were exposed to ENU and one week later exposed for 4 weeks to 2µM of IM. The 
number of outgrowing resistant clones is given relative to the total input cell number per 96 well 
plate. Data are representing mean± s.e.m. of 3 independent experiments; * indicates p<0.0001. 
 
32D-BA and 32D-BA-ICSBP cells were exposed with the randomly acting 
mutagen, ENU (N-ethyl-N-nitrosourea) followed by IM treatment at 2µM 
concentration and wells showing outgrowth of viable cells after 21-28 days were 
counted as IM resistant clones. Unexpectedly, significantly more IM-resistant 
colonies emerged in 32D-BA-ICSBP cells as compared to 32D-BA cells, but only if 
cells were treated prior to IM-exposure with ENU (Figure 28). This suggests that 
the absence of ICSBP expression limits the development of kinase point mutations. 
Indeed, IM resistant CML patients show much less frequently kinase point mutation 
than IM resistant Ph+ALL patients. 
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Figure 29: Effect of Bcl-2 over expression and chemical mutagenesis by ENU 
on kinase point mutation rates. Cell-based BCR-ABL kinase point mutation assay. 32D-
BA-ICSBP-Bcl-2 cells were exposed to ENU and one week later exposed for 4 weeks to 2µM of IM. 
The number of outgrowing resistant clones is given relative to the total input cell number per 96 well 
plate. Data are representing mean± s.e.m. of 3 independent experiments; * indicates p<0.001, 
Since ICSBP regulated apoptosis response to IM, we asked whether the increased 
rate of point mutations in presence of ICSBP is due to increased apoptosis 
sensitivity. Such a link would be novel, as little is known about the nature of kinase 
mutaions. We therefore over-expressed the anti-apoptotic Bcl2 gene and asked 
whether this prevented the increased mutagenesis rate in 32D-BAI-Bcl2 and 32D-
BA-Bcl2 cells. Although over-expression of Bcl-2 could restore the apoptosis 
induced by IM in 32D-BA-ICSBP cells, it failed to prevent the increased rate of 
kinase point mutations development (figure 29).  
5.2.5 PCR array targeting mouse DNA damage signaling pathway 
To explore how ICSBP controls ENU induced point mutagenesis in BCR-ABL 
transduced cells, a DNA damage signaling pathway specific PCR Array was 
performed. The expression of 84 genes involved in DNA damage signaling 
pathways were analyzed in 32D-BA and 32D-BA-ICSBP cells treated with 
50µg/ml ENU for 6 hrs. The genes targeted were associated with the ATR/ATM 
signaling network and transcriptional targets of DNA damage response. Out of 84 
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genes 52 genes were found to be down-regulated and 8 genes were up-regulated in 
32D-BA-ICSBP cells as displayed in 3D profile picture. 
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Figure30: PCR array targeting mouse DNA damage signaling pathway. 
Graphical display of comparative gene profiling data, shown as 3D profiler picture. Each column 
represents ct value of individual gene relative to housekeeping gene. 
To confirm the data obtained from the PCR array, 32D-vector, 32D-ICSBP, 32D-
BA and 32D-BA-ICSBP cells were treated with 50µg/ml ENU for 6 hrs and 
quantitative RT-PCR of selected candidate genes from PCR array was performed. 
Expression of 13 DNA repair pathway genes which include cell cycle related gene 
(chek1, hus1 and tlk1), base excision repair gene (parp2, mbd4, mpg, mutyh and 
ogg1), damaged DNA binding gene (xrcc2), mismatch repair gene (pms2 and 
pold3), apoptosis and other gene related to DNA repair (mbd4 and mgmt) were 
analyzed by quantitative RT-PCR (figure 31).  
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Figure 31: 32D-vector, 32D-ICSBP, 32D-BA and 32D-BA-ICSBP cells were treated with 
50µg/ml ENU for 6 hours. Expression of indicated DNA repair gene was quantitated. Each column 
represents gene expression relative to gapdh (mean±s.e.m.). Results shown here were obtained from 
3 independent experiments. 
Only the expression of apoptosis and DNA repair related gene mgmt was 
significantly up-regulated in 32D-ICSBP cells compared to 32D-vector after 
treatment with ENU. Expression of mgmt was higher in 32D-BA-ICSBP compared 
to 32D-BA cells; expression was further increased after treatment with ENU.   
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6 DISCUSSION  
Chronic myeloid leukemia (CML) is a clonal disorder of hematopoietic stem cells, 
caused by the aberrant expression of the BCR-ABL fusion protein (Ben-Nun, 
1986; Rowley, 1973; Rudkin et al., 1964). IM mesylate is a specific inhibitor of 
BCR-ABL and induces high rates of stable complete cytogenetic remissions 
(CCR) in chronic phase of CML (Druker et al., 2006; Hochhaus et al., 2009). 
However, despite long-term IM therapy, BCR-ABL-mRNA and BCR/ABL-
positive CFU remain detectable during CCR (Bhatia et al., 2003; Druker et al., 
2006; Hughes et al., 2003). CML persistence supposedly results from an inherent 
insensitivity to IM of the CML stem and progenitor cells (Graham et al., 2002; 
Jorgensen et al., 2007).  
A large body of evidence suggests that BCR-ABL overexpression in primitive 
(lin- CD34+CD38-), and mature (CD34+CD38+) progenitors contributes to the 
failure of IM to eradicate CML (Copland et al., 2006; Jamieson et al., 2004; Jiang 
et al., 2007a; Jiang et al., 2007b). However, the BCR-ABL expression level in 
persisting clones, and the impact of long term IM therapy on eradication of CML 
in different bone marrow compartments are still largely unknown.  
Abe et al. recently reported that residual disease accumulates in the lin-
CD34+CD38- fraction (Abe et al., 2008). When comparing BCR-ABL transcript 
level in whole marrow compartments from FD and MMR patients, we also 
noticed that the BCR-ABL expression goes down in the primitive (and mature) 
fraction, but also observed that residual disease remains detectable in the 
committed populations. We concluded from this, that IM is efficacious in all bone 
marrow compartments - independently from the proliferation status. In line with 
this, increasing clinical evidence suggests that long-term exposure to IM may have 
sustained effects on the viability of bone marrow cells including CML stem cells. 
For example, a significant proportion (41%) of CMR patients remained 
progression free at the molecular level after IM discontinuation (Mahon et 
al.,2010).  
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We specifically addressed the question, whether BCR-ABL overexpression may 
support long-term survival of CML clones under IM therapy. Intriguingly, we 
found that persisting primitive and mature BCR-ABL-positive clones (CFU) 
isolated from MMR patients regularly expressed significantly less BCR-ABL than 
FD CML CFU. This suggested that eradication of BCR-ABL -overexpressing 
clones present at FD could be an important requirement for the establishment of a 
MMR, which has an excellent long-term prognosis (Druker et al., 2006; Hughes et 
al., 2003; Press et al., 2006).  
In turn, if IM fails to eliminate these, supposedly “dangerous” BCR-ABL -high 
expresser clones, it would be tempting to speculate that the odds for evolution of 
secondary IM resistance, emerging from these clones, will increase. Indeed, 
patients treated in progressed phases of CML overexpress BCR-ABL (Elmaagacli 
et al., 2000; Gaiger et al., 1995; Guo et al., 1991) and regularly encounter IM 
resistance (Druker et al., 2001; Moravcova et al., 2004; Ottmann et al., 2002). 
There is also solid evidence for a direct link between BCR-ABL expression level, 
genetic instability and IM resistance (Koptyra et al., 2008; Koptyra et al., 2006; 
Sallmyr et al., 2008; Stoklosa et al., 2008). Using an immortalized, BCR-ABL-
dependent cell line model resembling blast crisis cells, we also provided such 
evidence by showing that BCR-ABL overexpression catalyzes mutagenesis and 
IM resistance development to a greater extent than chemical mutagenesis by ENU 
(Figure 5B). 
The mechanism, why exactly low BCR-ABL expression level may protect from 
IM-induced apoptosis is not entirely clear, but could be related to induction of 
weaker oncogenic dependence by less BCR-ABL. Modi et al. published 
previously very similar results to ours. They transduced normal primary human 
progenitor cells engineered to express low and high BCR-ABL levels and found a 
diminished IM sensitivity in case of lower BCR-ABL expression .  
Importantly, these findings do not contradict previous evidence that BCR-ABL 
overexpression may cause IM resistance (Hochhaus et al., 2002; le Coutre et al., 
2000). However, it must be acknowledged that the cellular context of BCR-ABL 
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expression might decisively control the biological effects of the oncoprotein 
during transformation, progression and drug resistance.  
In summary, our study supports the idea that achieving a MMR is associated with 
an eradication of CML precursors cells both, from the primitive and mature bone 
marrow fractions. It is also suggested that stable long-term persistence under IM is 
characterized by a selective survival of low BCR-ABL expressing precursors, 
which are less IM-sensitive, and genetically more stable. This would explain the 
low progression rates seen during MMR. Although therapeutic strategies targeting 
BCR-ABL-independent mechanisms of persistence may be rational (Burchert et 
al., ; Dierks et al., 2008; Gregory et al.), it is also possible that long-term BCR-
ABL kinase inhibition per se could prevent progression and even enable cure. 
Cure depends on the ability of IM to eradicate CML-stem cells. Our group has 
previously reported that ICSBP potently enhances the sensitivity of BCR-ABL 
transformed 32D cells to undergo apoptosis. ICSBP expression is lacking in CML 
by mechanism that are not entirely clear. It was reasonable to address to which 
extend and by which mechanism ICSBP expression modulates IM- sensitivity. In 
particular we asked whether apoptosis promoting effect of ICSBP controls the rate 
of kinase point mutation induction as the most important IM-resistance 
mechanism currently known. We stably tranduced 32D-BA and 32D-BA-ICSBP 
cells with Bcl2 to decrease the sensitivity of cells to undergo apoptosis in presence 
of IM (figure25).  
However, whether apoptosis sensitivity can also regulate drug resistance 
development is not known. ICSBP itself regulated apoptosis sensitivity, but has 
also been shown to modulate somatic hypermutation (SHM) and class switch 
recombination (CSR) (Zhou et al., 2009) in mature B-cells, where it is 
overexpressed. Saberwal et al. have recently shown that ICSBP activates promoter 
cis element of Fanconi F (FANCF) gene which participates in repair of cross 
linked DNA (Saberwal et al., 2009). Thus ICSBP may regulate IM resistance via 
two opposing effects: promotion of apoptosis, and also hyper-mutagenesis. This 
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would also mean, cells expressing ICSBP can better tolerate the physiological 
DNA damage, which normally triggers apoptosis.   
To test this hypothesis and to understand the role of ICSBP in development of 
kinase domain resistance, a cell based assay that uses ENU mutagenesis prior to 
selection of resistant clones was performed (Bradeen et al., 2006). ENU is a 
direct-acting alkylating agent that produces similar ratios of well-characterized 
ethyl adducts in DNA in cultured mammalian cells. Several O-ethyl-adducts, 
including O6-ethylguanine, O4-ethylthymine, and O2-ethylthymine, have been 
shown to direct mispairing of bases during DNA replication in vitro (Cosentino 
and Heddle, 2000). Since 32D BA-ICSBP cells are more sensitive to IM induced 
cell death compared to 32D-BA cells, a lower mutation rate could be expected in 
32D-BA-ICSBP cells. The contrary was the case, significantly higher IM 
resistance rate was observed in 32D-BA-ICSBP cells when compared to 32D-BA 
cells. Next we wanted to know whether over-expression of Bcl2 can alter 
increased mutation rate of BCR-ABL transformed cells. Although, overxepression 
of Bcl-2 in 32D-BA-ICSBP cells revert the IM induced cell death but failed to 
change the mutation rate in this cell system. Thus, lack of ICSBP expression in 
CML not only confers IM drug resistance, but also limits the frequency of point 
mutation development in a myeloid cell context. This would explain the lower 
rates of point mutations found in IM-resistant CML as opposed to BCR-ABL 
positive, IM-resistant ALL. In this study we also examined the relationship 
between ICSBP and mutagenesis in BCR-ABL transformed cells by PCR array. 
From this array, mgmt could be a potential target of ICSBP to explain the 
increased mutation development but further detailed investigation is required to 
unravel the mechanism. 
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